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Summary 
Effective prediction of diagnosis and prognosis in cancer is an important step for selection of a 
suitable treatment regimen. In this dissertation, the importance of using antibody microarray for 
effective diagnosis and prognosis of cancer was studied using bladder and gastric cancers.  
In the first part of study, establishment of a protein signature to predict recurrence of non-muscle 
invasive bladder cancer was aimed at. Antibodies against cancer-related proteins were spotted 
and proteins from recurrent and non-recurrent non-muscle invasive bladder cancer tissues 
incubated. The protein profiles of the samples were analyzed for statistical significance and 
differential expression of proteins among the cancer groups. After a series of analysis using 
bioinformatic tools, a 20 protein-signature predicting recurrence of non-muscle invasive bladder 
cancer was identified along with important molecular mechanisms underlying recurrence.  
High grade gastric adenocarcinomas are often lethal with metastasis and frequent recurrence. 
The second study concentrated on more personalized cancer medicine by direct comparison of 
healthy controls and gastric adenocarcinoma tissues from the same patient. Antibody microarray 
was used to study the protein profiles of gastric cancer by incubating protein samples from 
healthy controls in tandem with the cancer protein from the same patient. Statistically and 
clinically significant proteins were identified including a 16 protein signature for betterment of 
individual-based cancer treatment regimen. Identified biomarkers included known therapeutic 
targets such as VEGFA, S100A9 and newly identified markers like OCLN and TIA1.  
The analyses on two cancer types revealed two different protein signatures with high specificity 
and sensitivity. Moreover, our findings were clinically relevant and superior to many other 
approved available methods for diagnosis and prognosis. 
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Zusammenfassung 
Die effektive Diagnose und Vorhesage der Prognose einer Krebserkrankung sind wichtige 
Schritte für die Auswahl eines geeigneten Behandlungsschemas. In dieser Dissertation wurde die 
Bedeutung von Antikörper-Microarrays für die effektive Diagnose und Prognose von 
Krebserkrankungen am Beispiel von Blasen- und Magenkrebs untersucht.  
Das Ziel des ersten Teils der Arbeit war die Etablierung einer Proteinsignatur zur Vorhersage 
eines Rezidivs bei nicht-muskulärem invasivem Blasenkrebs. Antikörper gegen krebsrelevante 
Proteine wurden auf Microarrays aufgebracht und mit Proteinen aus Tumorgeweben von 
rezidivierendem und nicht-rezidivierendem, nicht-muskulärem invasivem Blasenkrebs inkubiert. 
Die Proteinprofile der Proben wurden auf statistische signifikante Unterschiede geprüft und die 
differentielle Expression der Proteine zwischen den unterschiedlichen Krebsarten analysiert. Mit 
Hilfe von bioinformatischen Auswertungsmethoden konnte eine Proteinsignatur bestehend aus 
20 Proteinen zur Vorhersage eines Rezidivs bei nicht-muskulärem invasivem Blasenkrebs sowie 
wichtige, dem Rezidiv zugrundeliegende molekulare Mechanismen identifiziert werden.  
Magen-Adenokarzinome in fortgeschrittenen Stadien verlaufen häufig tödlich, mit 
Metastasierung und hoher Rezidivrate. Der zweite Teil der Arbeit konzentrierte sich stärker auf 
personalisierte Krebsmedizin. Hierzu wurden Kontrollen aus gesundem Gewebe und 
Gewebeproben aus dem Magen-Adenokarzinom eines Patienten direkt miteinander verglichen. 
Unter Verwendung eines Antikörper-Microarrays wurden die Proteinprofile von Magenkrebs 
untersucht, indem Proteinproben aus den gesunden Kontrollproben und Tumorproben des 
gleichen Patienten zusammen inkubiert wurden. Statistisch und klinisch signifikant 
unterschiedlich experimente Proteine einschließlich einer Proteinsignatur aus 16 Proteinen zur 
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Verbesserung eines individualisierten Krebs-Behandlungsschemas wurden identifiziert. Die 
identifizierten Biomarker umfassten sowohl bekannte therapeutische Targets wie VEGFA und 
S100A9 als auch neu entdeckte Marker wie OCLN und TIA1. 
Die Analyse zweier Krebsarten ergab zwei unterschiedliche Proteinsignaturen mit hoher 
Spezifität und Sensitivität. Darüber hinaus waren unsere Ergebnisse klinisch relevant und vielen 
anderen anerkannten und verfügbaren Methoden zur Diagnose und Prognose überlegen.  
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1 Introduction 
1.1 Cancer 
Cancer is a non-communicable disease with high complexity and heterogeneity. It is the second 
leading cause of death after cardio-vascular diseases (Lozano et al., 2012). 13% of all death 
occurrences in world are caused by cancers. Approximately, five hundred out of a hundred 
thousand people are at high risk of cancer occurrence in their life time (WHO, 2009). Cancer 
nomenclature depends on the part of the body they originate from. All types of cancers are 
clinically distinct to each other but they all develop from uncontrolled cell growth resulting in 
formation of tissue mass of unstructured cells called tumor. Cancer is classified into two general 
types based on their aggressiveness in growth. Benign tumors are those that grow without 
invading other adjacent tissues. Tumors that invade nearby tissues and often organs are called 
malignant tumors. Malignant tumors often infiltrate into the blood stream, travel to other distant 
areas from their organ of origin and form colonies of tumors there. This process is called 
metastasis and this potential of tumors best describes the aggressiveness of the corresponding 
cancer (Weinberg, 2007). The metastatic cancers more lethal that they account of over 90% of all 
cancer related deaths (WHO, 2009). 
Cancer is a disease of malfunctioning cells because the native tissue is both structurally and 
functionally disorganized in such a way that the immune responses are often evaded or 
suppressed. A transformation of a single cell within an organism can lead to formation of a 
tumor. This transformation can be facilitated by cancer causing agents like free radicals, toxins, 
UV exposure and viruses for example human papilloma virus (HPV).  Most of these agents cause 
functional mutations in DNA (Weinberg, 2007). Mutations are known to be spontaneous but 
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with high rarity in human body. Various safeguard mechanisms facilitate human body to protect 
it from serious cellular defects and mutations. Mechanisms like DNA damage repair, cell cycle 
arrest, deregulation of cellular energetics are normally active in cells. For example, DNA repair 
system removes a part of mutated DNA that might happen during the DNA replication process. 
Cell division process, highly controlled normally is arrested when the cells undergo severe 
damage due to mutations or stress. In certain cases when a fundamental damage happen to DNA 
or cell itself that cannot be repaired, then cells undergo a process of programmed cell death also 
called as apoptosis (Alberts B, 2007).  
Most types of cancers arise when the above mentioned mechanisms do not work properly, 
especially under constant dysregulation of the genes involved in these key processes. Based on 
their activities, these self-protective genes are classified into two types: oncogenes and tumor 
suppressor genes. Growth-promoting genes that contribute to carcinogenesis by favoring the 
tumor cells to evade various growth control signaling mechanisms are called oncogenes. Tumor 
suppressor genes, often down-regulated in cancers are generally necessary for cells to maintain 
the important growth control barriers and balancing proliferating ability and death of the cells 
(Weinberg, 2007). Apart from these genes, several other mechanisms like angiogenesis, 
promoting inflammation and self signaling for proliferation of cells also facilitate cancer 
development (Hanahan and Weinberg, 2011). All the above mentioned processes account for the 
multistep process of carcinogenesis which makes treating the disease a challenge for modern 
biologists (Hanahan and Weinberg, 2011).  
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1.1.1 Bladder cancer 
Bladder cancer is the fourth most common cancer in men and ninth most common cancer in 
women. It accounts for more than 3% of total cancer related deaths in a year (Siegel et al., 2012). 
According to estimations by world health organization (WHO), hundred and fifty thousand 
people die every year of bladder cancer and it belongs to highly monitored post-operative 
cancers (Jacobs et al., 2010; WHO, 2009). Though the cancer is less lethal than many other 
major cancer types, the cost of treatment and periodical surveillance of the patients are rather 
expensive and often result in disappointing results (Sanchez-Carbayo and Cordon-Cardo, 2007). 
Cancers in bladder are clinically classified into two major types based on the types of cells 
cancer develop from, urothelial cell carcinomas which constitute of 95% of malignant bladder 
cancers and squamous cell carcinoma that constitute 5% of bladder cancers (Luis et al., 2007). 
1.1.1.1 Urothelial cell bladder cancer 
Pathologically, urothelial cell cancers are classified into superficial muscle or non-muscle 
invasive cancers and muscle invasive cancers based on their invasiveness. About 75% to 85% 
newly diagnosed bladder cancers are non-muscle invasive cancers (grades Ta and T1) and 15% 
to 25% are muscle invasive bladder cancers (grades T2 and T3) (figure 1). Even after an initially 
successful treatment by complete surgical resection of the tumors, 60% to 70% of the tumors will 
recur and 10% to 30% will progress to become muscle invasive cancers. Most of the muscle 
invasive cancers are also metastatic (Jacobs et al., 2010). Most of the non-muscle invasive 
tumors recur within five year after the surgical resection of the primary tumors. Regular 
surveillance cystoscopy and urine cytology is employed every three months during the first two 
years after resection, at longer intervals over the next two years, and annually thereafter (Montie 
et al., 2009). The lifetime surveillance costs right from pre-operative phases ranges from US$ 
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99,000 to US$ 121,000 (Avritscher et al., 2006). Above the financial burden, the physical and 
psychological stress, the patients are under is more important. Patients live in a state of 
uncertainty and are confronted with the possibility of yet another cancer diagnosis every three 
months of continuous surveillance (Jacobs et al., 2010; Luis et al., 2007).    
                                         
Figure 1. Anatomy of bladder- grading of urothelial cell carcinoma based on their depth of 
invasion (grades Ta to T3b). Ta tumors do not invade basal muscle or lamina propria and T1 do 
not invade muscle (Adapted from department of urology at Michigan urology centre, University 
of Michigan). 
1.1.1.2 Prognostic assessment of non-muscle invasive bladder cancer 
Most prognostic assessments of non-muscle invasive bladder cancer usually employ several 
features of tumors like multifocality, clinical grading, size and stage (Dubosq et al., 2012). Many 
immuno-histochemical markers have been proposed but in clinical settings, the practice of these 
markers has very less impact (Matsushita et al., 2011). Molecules like proliferation activators, 
proto-oncogenes and caveolins at mRNA level are also being used with not much correlation to 
the recurrence of the cancer (Dubosq et al., 2012; Mitra et al., 2009). Epigenetical modifications 
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in promoter sequences are being implemented as predictors of tumor progression (Jeong et al., 
2012). Lower levels of galectin-8 in tumor cells compared to healthy controls are known to 
predict recurrence of non-muscle invasive cancer but without great specificity (Kramer et al., 
2011). Mutations in TP53 are also studied as predictors of high risk for recurrence (Andreasson 
et al., 2008; Dexlin et al., 2008). Apoptosis regulators like CASP3, BCL2 and TP53 in 
combination with other genes predict the outcome of bladder cancer in non-muscle invasive 
patients (Korkolopoulou et al., 2000). However, no dependable biomarker or a set of markers 
presently exist to predict recurrence with clinically significant accuracy in non-muscle invasive 
bladder cancer (Babjuk et al., 2008; Babjuk et al., 2011; Dubosq et al., 2012). Thus, biomarkers 
for effective prediction of recurrence in non-muscle invasive bladder cancer can dramatically 
reduce the burden caused by the disease on patients and extremely high financial need for health 
care.  
1.1.2 Gastric cancer 
Gastric cancer is second most common in mortality among cancers worldwide, mostly occurring 
in developing nations (Dicken et al., 2005). According to WHO estimations, gastric cancer leads 
to seven hundred and thirty seven thousand deaths every year which is 10% of overall cancer 
related deaths worldwide (Dicken et al., 2005; WHO, 2009).  The mortality rate has remained 
unchanged over the past three decades despite advancement of surgical techniques and 
therapeutics. Gastric cancers are generally highly incident in patients over forty five years old, 
hence the mortality rate is quite high despite curative therapy most commonly involving surgical 
resection of whole stomach or a part of it. The treatment strategy and response are quite poor 
such that over all five year survival rates rage about 10% to 25% (Takeno et al., 2008).  
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Besides the high number of incidence and mortality, gastric cancer is a heterogeneous cancer in 
terms of clinical and pathological classification, genomic and proteomic background of the 
tumor mass and clinical outcomes (Zheng et al., 2004). Gastric cancer types are named after their 
cells they originate from. Most of the diagnosed gastric cancers are adenocarcinomas (95%), 
other types include squamous cell carcinoma, neuroendocrine tumors, stromal tumors and gastric 
lymphoma (Dicken et al., 2005; Zheng et al., 2004). 
1.1.2.1 Gastric adenocarcinoma grading and characteristics 
Gastric adenocarcinoma arising from secretory epithelia in the inner lining of gastric mucosa is 
the most aggressive form of gastric cancers. Based on the invasiveness of the tumor and 
differentiation of the cells, adenocarcinoma is clinically and pathologically graded into four 
types (figure 2) (Dicken et al., 2005). Most of the adenocarcinomas diagnosed belong to 
advanced stages (T3/T4) of the cancer accompanied by lymph node metastasis. The association 
of numerous lymph nodes morphologically with stomach tissues enables irresistible metastasis of 
tumor cells in advanced stages of the cancer (Senapati et al., 2008). Furthermore, advanced 
stages of gastric adenocarcinoma recur at relative higher rates of 40% to 70% after the curative 
surgical resection of primary tumor. Routine surveillance by means of endoscopy followed by 
adjuvant chemotherapy after primary resection leads to a median survival of nineteen months. In 
case of limited surveillance it drops to just eight months. Advanced stages of carcinoma without 
curative resection of tumors have a median survival rate of merely five months (Dicken et al., 
2005). Such low survival rates combined lymph node metastasis make treatment options not so 
much responsive and in turn lead to increased mortality (Dicken et al., 2005; Pietrantonio et al., 
2013; Zheng et al., 2004). 
 
Introduction 
 
 
10 
 
                                       
Figure 2. Anatomy of stomach- staging of gastric adenocarcinoma based on their extent of 
invasiveness (grades Ta to T4). Ta tumors originate at the inner lining and slowly protrude out 
invading other layers of stomach. T4 tumors are highly metastatic (Adapted from cancer research 
UK-homepage for gastric cancers). 
1.1.2.2 Biomarkers and treatment in gastric adenocarcinoma 
Gastric adenocarcniomas are often diagnosed merely by the localization of the tumor cells and 
their invasiveness. There are very few molecular biomarkers available to grade them according 
to their invasiveness (Pietrantonio et al., 2013). Diagnosis based on the transcript levels of p53 
and mutations in APC genes predicted gastric cancer but failed to differentiate the type of tumor 
(Zheng et al., 2004). Growth factor receptors like EGFR, c-met and ERBB2 have been used as 
predictors of later stages of malignancy but with much instability. CCL18 combined with certain 
T-cell receptors are employed as prognostic indicators in lower stages of gastric cancer (Leung et 
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al., 2004). Epithelial-mesenchymal transition marker proteins like E-cadherin are also used as 
predictors for higher stages of gastric adenocarcinomas. Certain cytokines are used as predictors 
of prognosis in gastric cancers associated with Helicobacter pylori infection but they do not have 
much significance in prediction of other types of adenocarcinoma (Ellmark et al., 2006).  
Many promising molecular biomarkers like S100A9, VEGFA and mucin family of proteins are 
also tested as potential therapeutic targets. Despite recent developments in gene sequencing and 
molecular diagnostics, many of these biomarkers are inconsistent in predicting a unanimous 
treatment regimen. Few treatment strategies have been introduced but molecular complexity and 
drug resisting capability of the cancers make the treatment of adenocarcinomas nearly 
impossible. Nevertheless, many biomarkers are being evaluated by various clinical trials to 
identify individual-based criteria and establish customized personal therapeutic approaches 
(Pietrantonio et al., 2013). The best treatment regimen available so far for higher stages of gastric 
cancer is curative surgical resection of the tumor followed by adjuvant chemotherapy with 
oxaliplatin and capecitabine. These two agents are reportedly highly efficient combined with less 
toxic effects and side-effects (Cunningham et al., 2010). Unfortunately, clinical trials on different 
biomarkers are experiencing critical ignorance such that most fail rather than considered as 
potential targets. Thus, introducing new therapeutic targets and predictive markers along with 
immuno-based screening tools will enable developing patient-specific chemotherapy in turn 
optimal drug efficiency and minimal adverse effects.  
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1.2 Antibody microarrays in cancer  
Omic technologies are excellent tools for both diagnostic and prognostic biomarker identification 
in cancers, a disease with high molecular and metabolic complexity. DNA microarrays are 
widely employed for initial screening studies on biomarkers at transcript levels in a wide variety 
of diseases. Inconsistency in validation of biomarkers identified by various genomic technologies 
led to the emergence of proteomic applications in biomarker discovery. Antibody-based 
technologies are extremely advantageous in biomarker discovery as they use biological end 
product which indulge in vital cellular activities (Michaud et al., 2003). NHS–based protein 
labeling methods provide a platform for large scale analysis of antibodies. Optimizing various 
factors including sensitivity and specificity for targeting analytes in low quantities brought in a 
new method of proteomic analysis (Wingren et al., 2007). Thus antibody microarrays are 
relatively a new tool for an analysis of protein abundance in parallel and highly multiplexed 
manner (Brennan et al., 2010) (figure 3).  
Antibody microarrays are extremely different tissue microarrays where the interpretation and 
validation of enriched targets are often subjected to differing opinions among individuals. 
Another advantage antibody array has over tissue microarray is the use of non-invasive body 
fluids like urine, saliva and plasma (Alhamdani et al., 2009). Solid supports like glass slides 
coated with chemical binders are used to immobilize antibodies on the glass surface. Cancer-
related antibodies are used for the production of antibody arrays in large scale (Kusnezow et al., 
2003). The number of targets used in the arrays varied from mere hundred to as high as thousand 
in fact with higher specificity and sensitivity (Sanchez-Carbayo et al., 2006; Schroder et al., 
2010). Studies involving protein extracts from tissues and cells are rarely done using antibody 
microarrays due to technical aspects (Hoheisel et al., 2013). However, optimized protocols and 
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detailed assessment are being established which permit antibody microarray with high accuracy 
and reproducibility for effective cancer diagnosis and prognosis (Alhamdani et al., 2010; 
Schroder et al., 2010). Recently, higher sensitivity detecting single molecules using antibody 
microarrays have been reported (Schmidt et al., 2011). Thus, antibody microarray being an 
immuno-based assay, can bridge the gap between effective diagnosis and personalized cancer 
medicine.  
             
Figure 3. Proteomic technologies being employed for effective cancer diagnosis and 
personalized cancer medicine. (Adapted from Brennan et al 2010 Nature reviews cancer). 
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1.3 Aim  
In this dissertation, potentiality in using antibody microarray as a tool for effective cancer 
diagnosis and prediction of prognosis is studied.  
The first part of the study is aimed at predicting recurrence of non-muscle invasive bladder 
cancer. For this purpose, twenty five non-muscle invasive bladder cancer samples with a 
minimum of five year follow-up time after the initial surgical resection were analyzed using 
antibody microarray. After the analysis, the identified protein signature would be helpful for the 
prediction of recurrence in non-muscle invasive bladder cancer and to establish a signature-based 
treatment regimen for bladder cancer patients. 
The second part of the study is aimed at identifying more personalized biomarkers for effective 
diagnosis and treatment of gastric adenocarcinomas. Thirty cancer tissues and healthy control 
tissues from the same patient were analyzed using antibody microarray to identify a significant 
protein profile. Identified protein profile will provide valuable insights on tumor development in 
gastric adenocarcinoma. The identified protein profile will not only help in an individual-based 
treatment regimen for gastric cancer treatment but also will identify more therapeutically 
important targets. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Instruments 
Instrument                                                            Manufacturer 
12-channel-pipette Biohit proline                          Biohit, Helsinki, Finland 
96-well flat-bottom block                                      Qiagen, Hilden, Germany 
96-well reaction plates                                           Steinbrenner, Wiesenbach, Germany 
6-well culture plates                                               Steinbrenner, Wiesenbach, Germany 
24-well culture plates                                             Steinbrenner, Wiesenbach, Germany 
Automatic developing machine                             Amersham, Freiburg, Germany 
Beckmann GS-6KR centrifuge                              Beckmann, Wiesloch, Germany 
Centrifuge 5810 R                                                 Eppendorf, Hamburg, Germany 
Centrifuge 580 R                                                   Eppendorf, Hamburg, Germany 
Cell culture incubator                                            Koettermann, Haenigsen, Germany 
Cell culture microscope                                         Carl Zeiss, Jena, Germany 
Cell viability analyzer                                            Beckmann, Wiesloch, Germany 
Dismembrator                                                        B.Braun Biotech, Melsungen, Germany 
Dry block heating system                                      Grant instruments, Cambridge, UK 
Electrophoresis power supply                                E-C apparatus corporation, USA 
Epoxysilane-coated slides Nexterion-E                 Schott, Jena, Germany 
Infinite m200 multimode reader                            Tecan Grp Ltd, Maennedorf, Switzerland 
MicroGrid II Array-Roboter                                  Biorobotics, Cambridge, UK                                    
Mini-protein electrophoresis system                      Bio-Rad Laboratories, Munich, Germany 
Power supply E835                                                Hoefer, CA, USA 
QuadriPERM plates                                               Vivascience, Hannover, Germany 
ScanArray 4000XL                                                Perkin Elmer, Massachusetts, USA 
Sigma 2k15 centrifuge                                           M&S laborgeraete gmbh, Wiesloch, Germany 
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SlideBooster hybridization station                        Advalytix, Munich, Germany 
SMP3B stealth pins                                               Telechem, CA, USA 
TE70 PWR semidry transfer unit                          Amersham, San Fransisco, USA 
Vortex                                                                    Scientific industries Genie-2, New York,USA 
Water bath SW22                                                  Julabo Labortechnik, Seelbach, Germany 
 
2.1.2 Chemical reagents, enzymes and general materials 
Reagent                                                                  Supplier 
2-Mercaptoethanol                                                 Roche Diagnostics, Mannheim, Germany  
6-Aminocaproic acid                                              Sigma-Aldrich, Munich, Germany 
12-Maltoside                                                          Sigma-Aldrich, Munich, Germany 
Acetic acid                                                             Mallinckrodt Baker, Greisheim, Germany 
Acrylamide (30%w/v)/Bisacrylamide                   Bio-Rad Laboratories, Munich, Germany 
(29/10.8%) 
Ammonium peroxydisulfate (APS)                       Sigma-Aldrich, Munich, Germany 
ASB-14                                                                  Sigma-Aldrich, Munich, Germany 
Bovine serum albumin (BSA)                               Sigma-Aldrich, Munich, Germany 
Bromphenol blue                                                   Sigma-Aldrich, Munich, Germany 
Chloroform                                                            Merck, Darmstadt, Germany 
CleanasciteTM lipid removal agent                         Biotech support group, New Jersey, USA  
Dimethylsulfoxide (DMSO)                                  Sigma-Aldrich, Munich, Germany 
ECL hyperfilm                                                       GE Healthcare Europe, Freiburg, Germany 
Ethylenediaminetetraacetic acid (EDTA)              Merck, Darmstadt, Germany 
Ethanol                                                                   Merck, Darmstadt, Germany 
Glycerin                                                                  Roth, Karlsruhe, Germany 
Glycine                                                                   Roth, Karlsruhe, Germany 
Hydrogen chloride (HCl)                                       Merck, Darmstadt, Germany 
Isopropanol (2-propanol)                                       Mallinckrodt Baker, Greisheim, Germany 
Magnesium chloride                                               Merck, Darmstadt, Germany 
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Membran Protran NCBA85                                    Whatman gmbh, Hassel, Germany 
Methanol                                                                 Merck, Darmstadt, Germany 
Milk powder (Skimmed)                                         Sigma-Aldrich, Munich, Germany 
Na2HPO4                                                                 Merck, Darmstadt, Germany 
NaH2PO4                                                                 Merck, Darmstadt, Germany 
NaOH                                                                      Merck, Darmstadt, Germany 
Natriumacetat                                                          Merck, Darmstadt, Germany 
Natriumazide                                                           Merck, Darmstadt, Germany 
Natriumchloride                                                      Merck, Darmstadt, Germany 
Natriumcitrate                                                         Merck, Darmstadt, Germany 
Na-cholate                                                               Sigma-Aldrich, Munich, Germany 
NP-40 substitute                                                      Sigma-Aldrich, Munich, Germany 
Nuclease free water                                                 Ambion, Austin, USA 
PMSF                                                                       Sigma-Aldrich, Munich, Germany 
Potassium Chloride                                                  Sigma-Aldrich, Munich, Germany 
Potassium dihydrogen phosphate                            Sigma-Aldrich, Munich, Germany 
Sodium Carbonate                                                   Sigma-Aldrich, Munich, Germany 
Sodium dodecyl sulfate (SDS)                                Sigma-Aldrich, Munich, Germany 
Spectra multicolor broad range protein ladder        Thermo Scientific, Rockford, USA 
Sulphorhodamine B (SRB)                                      Sigma-Aldrich, Munich, Germany 
T-PER tissue protein extraction reagent                  Thermo Scientific, Rockford, USA 
TEMED                                                                    Bio-Rad Laboratories, Munich, Germany 
Trichloro acetic acid (TCA)                                     Fisher Chemicals, Reading, UK 
Tris-Base                                                                  Sigma-Aldrich, Munich, Germany 
Tris-HCl                                                                   Sigma-Aldrich, Munich, Germany 
Triton-X100                                                             Sigma-Aldrich, Munich, Germany 
Tween-20                                                                 Sigma-Aldrich, Munich, Germany 
Tween-80                                                                 Sigma-Aldrich, Munich, Germany 
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2.1.3 Cell culture 
Reagent                                                                  Supplier 
DMEM                                                                    Gibco/Invitrogen, Karlsruhe, Germany 
DMEM/F12 (Ham)                                                 Gibco/Invitrogen, Karlsruhe, Germany 
Fetal Bovine Serum (FBS)                                    Gibco/Invitrogen, Karlsruhe, Germany 
L-Glutamine                                                            Gibco/Invitrogen, Karlsruhe, Germany 
Phosphate buffered saline (PBS)                            Gibco/Invitrogen, Karlsruhe, Germany 
Penicillin 1000u/ml-Streptomycin 100µg/ml         Gibco/Invitrogen, Karlsruhe, Germany 
RPMI                                                                       Gibco/Invitrogen, Karlsruhe, Germany 
Trypsin/EDTA solution                                           Gibco/Invitrogen, Karlsruhe, Germany 
 
2.1.4 Dyes and Kits 
Item                                                                         Supplier 
The blocking solution                                             CANDOR Biosci. gmbh, Wangen, Germany 
Dy-549-NHS                                                           Dyomics, Dresden, Germany 
Dy-649-NHS                                                           Dyomics, Dresden, Germany 
ECL prime western blot detection kit                     GE Healthcare Europe, Freiburg, Germany 
Novagen BCA protein assay kit                              Merck, Darmstadt, Germany 
siPORTTM NeoFXTM Reverse transfection kit         Ambion, Austin, USA 
 
2.1.5 Antibodies and synthetic RNAs 
Item                                                              Supplier                                             Dilutions 
Anti.TIA-1                                          Santa Cruz, Biotech. Inc., Texas, USA         1:1000       
Anti.S100A9                                       Santa Cruz, Biotech. Inc., Texas, USA         1:500       
Sec. antibody-Goat                             Santa Cruz, Biotech. Inc., Texas, USA         1:5000 
GAPDH-HRP conjugated                  Sigma-Aldrich, Munich, Germany                1:25000 
TIA1 siRNA-1                                   Qiagen, Hilden, Germany (SI00133098) 
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TIA1 siRNA-2                                   Qiagen, Hilden, Germany (SI00133105) 
TIA1 siRNA-3                                   Qiagen, Hilden, Germany (SI00133112) 
TIA1 siRNA-5                                   Qiagen, Hilden, Germany (SI00301917) 
TIA1 siRNA SMARTpool                 Dharmacon, Rockford, USA (M-013042-02-005) 
Allstars Negative control siRNA       Qiagen, Hilden, Germany (1027280) 
 
2.1.6 Cell lines 
Cell lines                Cellular origin        Tumorigenic           Source 
AGS                        Stomach                        Yes                  Cell lines service (300408) 
HGC-27                  Stomach                        Yes                  Cell lines service (300436)            
MKN-45                 Stomach                        Yes                  Dr. Christiane Dinsart, DKFZ   
 
2.1.7 Buffers and Solutions 
Solutions and Buffers                              Components 
APS                                                            10% APS w/v in ddH2O        
10X PBS                                                    137 mM NaCl 
                                                                   27 mM KCl 
                                                                   100 mM NaH2PO4  
                                                                                        17 mM KH2PO2  
                                                                   dissolved in ddH2O 
PBST                                                         10X PBS with 0.1% (v/v) Tween 20 
PBSTT                                                      10X PBS with 0.1% (v/v) Tween 20 and 
                                                                  0.1% (v/v) Triton-X 100      
10X TBS                                                   500 mM Tris.HCl 
                                                                  1500 mM NaCl  
                                                                  dissolve in ddH2O and pH 7.6          
TBST                                                        10X TBS with 0.1% (v/v) Tween 20  
10% SDS                                                  10% (w/v) SDS dissolve in ddH2O    
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Stacking gel buffer                                   1.5 M Tris.HCl 
                                                                  dissolve in ddH2O and pH 6.8       
Resolving gel buffer                                 1.5 M Tris.HCl 
                                                                  dissolve in ddH2O and pH 8.8           
10X SDS gel Tank buffer                         50 mM Tris-Base 
                                                                  400 mM glycine         
                                                                  10% (w/v) SDS 
                                                                  dissolve in ddH2O   
 Lysis buffer for protein isolation             500 µl of NP-40 
                                                                  1000 µl of  Na-Cholate 
                                                                  1000 µl of ASB-14 
                                                                  1000 µl of 12-maltoside 
                                                                  2000 µl of glycerol (99%) 
                                                                  1000 µl of sodium carbonate 
                                                                  167 µl of magnesium chloride 
                                                                  500 µl of EDTA.2Na 
                                                                  50 µl of PMSF 
                                                                  100 µl of protease and phosphotase inhibitor 
                                                                  0.4 µl of Benzonase (100U/µl) 
                                                                  2683 µl of ddH2O  
Western blot anode buffer I                      30 mM Tris-Base 
                                                                  20% (v/v) methanol dissolve in ddH2O  
Western blot anode buffer II                    5 mM Tris-Base 
                                                                  20% (v/v) methanol 
                                                                  dissolve in ddH2O            
Western blot cathode buffer                     20 mM 6-aminocaproic acid 
                                                                  20% (v/v) methanol 
                                                                  dissolve in ddH2O        
Milk-blocking buffer                                5% milk powder in 1XTBST    
Milk blocking buffer for microarray        10% milk powder in 1XPBSTT 
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2.2 Methods 
2.2.1 Selection and collection of samples for the study 
2.2.1.1 Bladder cancer samples 
Primary tumors were resurrected from patients with low-grade (stages Ta and T1) non-muscle-
invasive bladder cancer at the Department of Urology and Pathology of Henri Mondor Hospital 
in Paris, France. All subjects were informed with a written consent and the same was obtained 
from all subjects. The analysis was approved by the local ethics committee and all the 
experiments conformed to the principles set out in the WMA Declaration of Helsinki. Only 
samples were considered with a patient follow-up of at least five years post the surgical resection 
of the primary tumour. Nineteen patients experienced recurrence within the five years of follow-
up while six patients did not. In addition, three normal bladder tissue samples were available as 
controls. The age and gender of all the samples studied are equally distributed and none of the 
patients did receive any cancer-related therapy before sampling. The tissue samples were snap-
frozen in liquid nitrogen soon after resection to protect the tissue and cellular components. Then, 
the tissue samples were pulverized using dismembrator under deep freeze conditions (-50ºC) and 
protein isolation was carried out. 
2.2.1.2 Gastric cancer samples 
Primary tumors from patients diagnosed with high-grade and stage invasive gastric 
adenocarcinoma along with a part of the normal tissue surrounding the tumors were resurrected 
at the Department of Gastroenterology, University medical centre, Ljubljana, Slovenia. All 
subjects were informed with a written consent and the same was obtained from all subjects. The 
analysis was approved by the local ethics committee and all the experiments conformed to the 
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principles set out in the WMA Declaration of Helsinki. Twenty five pairs (normal and tumour) of 
tissue samples were collected from twenty five patients and the samples were snap-frozen in 
liquid nitrogen until further use to protect the tissue and cellular components. Then, the tissue 
samples were pulverized using dismembrator under deep freeze conditions (-50ºC) and protein 
isolation was carried out. 
2.2.2 General methods in molecular biology 
2.2.2.1 Protein isolation 
Homemade lysis buffer was used for the isolation of whole protein from tissues and cells.  
From Tissues 
Pulverized tissue was collected in eppendorf tubes and ice cold lysis buffer was added at a 
volume of 10 µl/1 µg of tissue. A disposable syringe with needle was used to break and tear the 
tissue and the solution was aspirated and suspended continuously. The eppendorf tubes were 
shaken gently for 10 minutes on ice and centrifuged for 5 minutes at 13,000 rpm in a table top 
centrifuge at 4ºC. The supernatant was collected in a fresh eppendorf tube and stored at -20ºC.  
From Cells 
Medium from the 6-well plates was aspirated and 60 µl of lysis buffer was added to each well of 
the plate. A cell scraper was used to spread the lysis buffer over the cells and to detach them. 
Lysates were transferred to eppendorf tubes and the tubes were gently shaken on ice for 10 
minutes. Then the tubes were centrifuged for 5 minutes at 13,000 rpm in a table top centrifuge at 
4ºC. The supernatant was collected in a fresh eppendorf tube and stored at -20ºC. 
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2.2.2.2 Lipid removal from protein samples 
Protein samples were often contaminated with lipids that made quantification and labeling of the 
samples difficult. CleanasciteTM was added to the samples to remove lipids. Cleanascite solution 
was added to the sample at a ratio of 1:2 and incubated for an hour at 4ºC with constant shaking 
at a very low speed. After centrifugation at 13,000 rpm for 5 minutes, the supernatant free from 
lipids was collected in a fresh eppendorf tube and the concentration was measured by BCA 
assay. Then the tubes were stored at -20ºC. The precipitate containing lipids was discarded.  
2.2.2.3 Protein quantification by BCA assay 
Total protein from both tissue samples and cells were quantified using Novagen BCA protein 
assay kit. This method involves the colorimetric detection of cuprous cation using bicinchoninic 
acid (BCA) which is formed by the reduction of Cu+2 to Cu+1 by the protein in an alkaline 
medium. BCA reagent A and reagent B were mixed at a ratio of 50:1 to make the BCA working 
reagent. 10 µl of BSA dissolved in lysis buffer and samples were pipette into the wells of a fresh 
96-well microtiter plate. 200 µl of the BCA working reagent was added to each well and the 
plate was incubated at 37ºC for 30 minutes. The absorbance was then measured at 562 nm and a 
standard curve of absorbance versus standard proteins (in µg) was prepared to determine the 
concentration of the samples. 
2.2.2.4 Western blot analysis 
10% SDS gels were used for resolving protein. 10% and 5% acrylamide/bisarcylamide were used 
respectively for resolving and stacking part of the gel. 0.06% (w/v) ammoniumpersulphate and 
0.1% (v/v) N, N, N’, N’ – tetramethylethylenediamine (TEMED) were used to induce the 
polymerization of the gel. 10 µg of protein with rotiload loading dye were boiled together for 5 
minutes and loaded into the respective slots in the gel. A prestained- protein ladder was also 
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loaded referring to the molecular weight. Electrophoresis of the gel was carried out for 90 
minutes at 135 V and 500 mA in 1X SDS-gel tank buffer. The transfer of polypeptides from the 
gel to a nitrocellulose membrane was carried out by TE70 PWR semidry transfer apparatus. A 
sandwich model was prepared by soaking Whatman filter papers in anode buffers I, II and 
cathode buffer. The membrane was activated in anode buffer II.                      
The stacking part of the gel was cut and the sandwich was assembled with the filter papers, 
membrane and the gel after which the semidry electrophoretic transfer was carried out for 60 
minutes at 35 V and 500 mA. To detect the transferred protein, after the transfer the membrane 
was blocked for 1h at room temperature with the milk blocking buffer. After blocking, the 
membrane was incubated with the diluted primary antibody over night at 4ºC. After incubation, 
the membrane was washed 3 times with 1XTBST and was incubated with secondary antibody 
conjugated with horse radish peroxidase for 1h at room temperature. Then, the membrane was 
washed for 3 times with 1XTBST and protein was detected by enhanced chemiluminescence 
(ECL) using the ECL prime western blot detection kit. The ECL substrate was prepared 
according to the manufacturer’s instructions and incubated on the membrane for 1 minute and 
the solution was drained off. Now, the membrane was kept on a clean plate inside the LAS 
Fujifilm 5000 machine and images were captured using a CCD camera on exposing the 
membrane gradually to the X- rays. Similarly, the procedure was repeated for the detection of the 
house keeping protein in the same membrane. 
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2.2.3 Methods in cell culture and related assays 
2.2.3.1 Routine maintenance of cells 
Cell lines were maintained at 37ºC and 5% CO2. MKN-45 cells were maintained in RPMI with 
4.5 g/L D-glucose supplemented with 10% fetal bovine serum (FBS), 1000 u/ml penicillin and 
100 µg/ml streptomycin and 2 mM glutamine. AGS cells were maintained in DMEM with 4.5 
g/L D-glucose supplemented with 10% fetal bovine serum (FBS), 1000 u/ml penicillin and 100 
µg/ml streptomycin and 2 mM glutamine. HGC-27 cells were maintained in DMEM/F12 (ham) 
with 4.5 g/L D-glucose supplemented with 5% fetal bovine serum (FBS), 1000 u/ml penicillin 
and 100 µg/ml streptomycin and 2 mM glutamine. All cells were passaged every 2 to 3 days and 
sub cultured in fresh medium.  
2.2.3.2 Transfection of cells 
All the RNA transfections in this study were carried out in 6-well or 96-well plates using 
siPORTTM NeoFXTM (Ambion) reagent. Reverse transfection by means of siPORTTM NeoFXTM 
involves simultaneous tranfecting and plating of cells. siPORTTM NeoFXTM transfection agent 
and the RNA molecules are mixed and distributed on the culture plates over which the cells are 
overlaid. The final transfection volume in a 6-well plate is 2.5 ml of medium containing 2 x 105 
cells per well and in a 96-well plate is 100 µl of medium containing 5 x 103 cells per well. As the 
transfection complexes are stable in presence of serum, no change of medium or other 
precautionary measures taken in case of traditional transfections methods are needed. The final 
concentration of the RNA molecules transfected ranges from 5 nM to 50 nM. After this 
procedure, the plates were maintained at 37ºC and 5% CO2. 
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2.2.3.3 Cell viability using Sulphorhodamine B (SRB) 
After 48 hours of incubation of cells at 37ºC, the plates were taken out and medium is discarded. 
10% (w/v) TCA was added to the wells and the plates were incubated at 4ºC for 2 hours to fix 
the cells. TCA is then discarded and the plates were rinsed with water and dried at 37ºC for 20 
minutes. 0.05% (w/v) of sulphorhodamine B (SRB) reagent was added to the wells and the plates 
were incubated for 30 minutes at room temperature in dark. The plates were washed for 3 to 4 
times with 1% (v/v) acetic acid to remove SRB reagent and then dried for 20 minutes at 37ºC.  
100 mM Tris was added to the plates and the plates were shaken for 10 minutes after which, the 
absorbance was measured at 570 nm from the stained cells and at 650 nm from blank after 
which, the results were tabulated for calculating the percentage of viable cells after transfection. 
2.2.4 Antibody microarray 
2.2.4.1 Selection of antibodies and generation of microarray  
In-house developed antibody microarray had 813 antibodies directed against 724 cancer related 
proteins. The antibodies were selected based on previous studies of transcription profiling 
involving many cancer entities and strong literature search on cancer related proteins. The list of 
antibodies is found in annexure A. The antibodies were printed on epoxysilane-coated Nexitron-
E slides using the contact printer MicroGrid-2 and SMP3B pins at a humidity of 40% to 45%. 
The buffer composed of 0.1 M carbonate buffer of pH 8.5 with 0.01% tween-20, 0.05% sodium 
azide, 0.5% dextran, 5 mM magnesium chloride and 1 mg/ml of antibody. Streptavidin 
molecules labeled with Cy3 or Cy5 were spotted as dye controls and the slides were allowed to 
quilibrate at humidity of 40% to 45% overnight and then stored at 4ºC in dry, dark conditions 
until further use.  
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Figure 4.  overview of production of antibody microarrays. Steps a to f constitute the proteome 
profiling of cancers using antibody microarrays. 
2.2.4.2 Labeling of protein samples 
Extracted and estimated protein samples were labeled at a dye/protein molar ratio of 1:18, 
assuming that the average weight of protein is 60 KDa. The NHS-esters of dye paris DY-549 
(Cy3) and DY-649 (Cy5) were used to label the protein samples. The protein samples were all 
adjusted to a concentration of 1 mg/ml and labeling was carried on in the dark in 0.1 M 
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carbonate buffer, pH 8.5 at 4ºC for 2 hrs. Later, the unreacted dye was quenched by adding 10% 
glycine in the dark at 4ºC for 30 minutes. The non-incorporated and inactivated dye molecules 
were removed from the samples by using zeba spin-desalting columns with a cutoff of 3.5 KDa 
and a buffer change to PBS according to the manufacturer’s recommendations. After dye 
removal, the labeled samples were stored at -20ºC until further use. 
2.2.4.3 Blocking of slides and Incubation of samples 
The slides were taken out and allowed to settle at room temperature for about 10 minutes. Then 
they were washed with 1X PBST in continuous agitation at room temperature for 4 times at 
regular time interval. Then the slides were blocked with 1 ml of the blocking solution from 
candor buffer on the slide booster instrument for 4 hrs at room temperature. The blocking 
solution was then removed and 10 µl of each of the labeled samples (Cy3 and Cy5) were added 
to 580 µl of the blocking solution from candor buffer such that the total incubation volume of 
600 µl kept ready for incubation. 600 µl of incubation solution was added to each slide and the 
incubation was carried on the slide booster instrument for 16 hrs at room temperature. After the 
incubation, the slides were washed with 1X PBST on the slide booster and then washed 4 times 
in continuous agitation at room temperature. The slides were quickly air dried using a strong 
clean air blower. 
2.2.4.4 Scanning and signal detection of slides  
Slides were scanned and the fluorescence of Cy3 and Cy5 were measured using ScanArray 
4000XL instrument. The slides were scanned at a resolution of 10 µm, maintaining constant laser 
power and photomultiplier (PMT). The excitation of Cy5 was achieved by a laser emission at a 
wavelength of 635 nm while Cy3 excitation was achieved by a laser emission at a wavelength of 
532 nm. Two separate images were made for each dye and were then quantified. 
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Figure 5.  Flowchart of the experimental procedure to analyse non-muscle invasive bladder 
cancer samples.  
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Figure 6.  Flowchart of the experimental procedure to analyse gastric cancer samples.  
2.2.4.5 Software used in image, data analysis and interpretation 
Software                                                       Manufacturer 
GenePix Pro 6.0                                            Axon Instruments, CA, USA 
LIMMA Package R-bioconductors              Fred Hutchinson cancer research centre, USA 
Chipster package (v1.4.6)                            CSC-IT centre for science, Espoo, Finland 
STRING 9.1 database for known and predicted protein-protein interaction. 
DAVID bioinformatics resources 6.7- functional annotation and microarray analysis 
KEGG (Kyoto Encyclopedia of Genes and Genomes)  Kanehisa Labs, Kyoto, Japan 
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2.2.4.6 Quantification of signal intensities from slides 
Image analysis was carried out using GenePix Pro 6.0 software where the images were uploaded 
into the software and overlaid one over the other. The spots in the merged image were analyzed 
primarily where by the yellow spots represented equal expression of the target protein in both 
channels and red, green colors representing the differentially expressed target proteins in either 
of the channels. Further quantification was done by .gal files which were placed over the merged 
image spots. The gal files were made as a source to carry information on the spots and 
corresponding protein targets. Thus the signal intensity from a spot in the image is transferred as 
information on a target protein. Similarly the raw signal intensities form each spot were 
calculated and stored as a valued table (.gpr files). Apart from the intensities of the spots the gal 
files also transfer the information on intensity of the background, number of pixels standard 
deviation and median etc. of both spot and background intensities.  
                          
Figure 7.  (a) A dual color picture of an antibody microarray slide (only a part) incubated with 
the bladder cancer samples. (b) spots showing the differential expression (colors yellow and 
green)                                                     
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2.2.5 Bioinformatics and statistical methods 
2.2.5.1 Data analysis by LIMMA bioconductors 
The tables with values from spot intensities (.gpr files) were analyzed using the LIMMA package 
of R-bioconductors (Smyth et al., 2005). The resulting data were normalized by the application 
of an invariant Loess method developed and described by the usefulness of the available 
reference samples (Sill et al., 2010). The sample pools and the individual samples were analyzed 
using a one-factorial linear model fitted with LIMMA which resulted in a t-test based on 
moderated statistics. Then the resulting p-values were adjusted for multiple testing by controlled 
discovery of false proteins according to the Benjamini and Hochberg methods (Smyth, 2004). 
The differential abundance of proteins in the samples were presented in log2 fold changes where 
highly abundant proteins had log2 values above 0(positive values) and less abundant proteins 
had values below 0(negative values). Adjusted p-values were also presented in log form and the 
proteins with p-values less than 0.05 were considered significantly abundant between two test 
classes. LIMMA bioconductors was also used for further analysis on the differentially abundant 
proteins which resulted in volcano plots, box plots and dot plots. Bladder cancer samples and 
gastric cancer samples (test set only) were analyzed using LIMMA bioconductors. 
2.2.5.2 Methods used in sample classification 
After normalization of the raw data, an unsupervised hierarchical cluster of samples was created 
to check the various technical and handling artifacts in the data. Then the highly significantly 
differentially abundant proteins from the LIMMA analysis were used to build a random forest 
classifier (Breiman, 2001). The samples were analyzed by building different test and training sets 
by the use of leave-one-out algorithm in a reiterated outer-loop. This was performed by the 
application of framework of R called comprehensive package for supervised classification 
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(CMA) (Slawski et al., 2008). After a serious of leave-one-out loops, the classification results 
were plot in appropriate ROC-curve and AUC plots.  
2.2.5.3 Data analysis by Chipster package 
A training set of Gastric cancer samples were analyzed using Chipster software package (v1.4.6. 
CSC, Finland). After image analysis using GenePix pro 6.0, the tables with values from spot 
intensities (.gpr) files were loaded in the Chipster software and analyzed. The intensity ratios 
were generated using the median signal intensities with local background of each spot in both red 
(DY-649) and green (DY-549) channels. By the application of a Loess method with a 
background correction offset [0, 50] for the normexp method, the intensity ratios were 
normalized . An unsupervised hierarchical cluster of samples was made with the normalized data 
to study and neglect (if any) technical and handling artifacts. The significance in differential 
abundance of proteins was tabulated by the application of empirical Bayes test with the p-values 
adjusted as per Benjamini-Hochberg method (Smyth, 2004). The empirical Bayes make use of a 
moderated t-statistic in which posterior residual standard deviations were applied rather than of 
ordinary standard deviations, which gave a far more stable inference when the number of arrays 
were small (Smyth, 2004). The proteins with an adjusted p-value of 0.05 and less than that were 
considered significantly differentially abundant in the samples. An unsupervised hierarchical 
clustering coupled with a boot-strap method was followed to get an optimized signature to 
classify the normal and tumor groups. The resulting list consisting signature proteins were then 
tabulated with their log fold change and adjusted p-values respectively. The total number of 
samples analyzed and classified based on the signature of proteins were then tabulated.  
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2.2.5.4 Interaction and pathway analysis 
The functions and interactions between the proteins were studied and evaluated using STRING 
9.1, open-source software (Szklarczyk et al., 2011). The list of significantly differentially 
abundant proteins were loaded into the software online and results reported interactions among 
the proteins were evaluated and compared to the pattern of abundance of the proteins in the 
sample sets. The functional significance of the various interactions were also evaluated and 
compared to the abundance pattern of the proteins. The desired results were then tabulated and 
separate figures interpreting the interactions were made. The list of significantly differentially 
abundant proteins and their pattern of abundance was loaded into KEGG pathway (Kyoto 
Encyclopedia of Genes and Genomes) and the resulting pathways were evaluated (Kanehisa et 
al., 2012). The resulting pathways were also used as a reference for detailed analysis of the 
abundant proteins.  
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3 Results 
3.1 Recurrence prediction in non-muscle invasive bladder cancer 
3.1.1 Hierarchical clustering of samples to study incubation batch effect 
In the present study, the protein samples from non-muscle invasive bladder cancer were 
compared for the identification of a protein signature to predict recurrence. The samples were 
analyzed using antibody microarrays constructed as mentioned in sections 2.2.4(1, 2 and 3) in 
methods. To also study the possible technical artifacts that may result, four samples were 
repeatedly incubated in different batches. As the incubations of the samples on the antibody 
microarrays were carried out on different time points, an unsupervised clustering of the samples 
was done after normalization of the data. In the hierarchical cluster, the samples were found 
equally distributed irrespective of the batch they were incubated on the arrays (figure 8). Most of 
the duplicates for example samples 1868, 4131 and sometimes even the triplicates for example 
samples 677-1, 2552 were clustered together in the hierarchical cluster (figure 8) referring to the 
presence of no technical artifacts such as handling, day of incubation, position of the slides in 
slidebooster and incubation of samples on different arrays itself. 
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Figure 8. H
ierarchical cluster analysis of the sam
ple set. The Euclidean distance and the average linkage m
ethod w
ere used. For 
each sam
ple, the identifier and the incubation batch are given. The incubation batches do not cluster. R
epeated sam
ples, 
how
ever, are located next or very close to each other. Sam
ples w
hose nam
es start w
ith the letter V
 represent healthy bladder and 
cluster next to each other. 
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3.1.2 Differential expression of proteins between normal bladder and non-      
muscle invasive bladder tumors 
Protein samples isolated from three normal bladder tissues (healthy), labeled and incubated in 
duplicates was compared with protein samples from twenty five non-muscle invasive bladder 
tumor tissues to check the differential abundance of proteins. Overall, sixteen proteins (adjusted 
p-value less than 0.05) were found to be significantly differentially abundant between tumor and 
normal tissues.  
         
Figure 9. Volcano plot summarising expression differences between samples from cancer and 
healthy patients. The Log-fold change and respective significance level as an adjusted p-value 
are given. The black dots above the red line indicate proteins with significantly (p<0.05) 
different expression.  
Cancer versus healthy controls 
 
Results 
 
 
38 
 
A volcano plot containing the details of the differentially abundant proteins is shown in figure 9. 
Among the significantly abundant proteins, Tumor necrosis factor receptor superfamily member 
10A (TNFRSF10A), Cyclin-dependent kinase inhibitor 1C (CDKN1C) and Lamina-associated 
polypeptide 2, Thymopoietin isoform alpha (LAP2A) were significantly very highly abundant in 
tumor samples with log2 fold change and adjusted p-value of (0.54, 0.0002), (0.32, 0.007) and 
(0.30, 0.0005) respectively. Similarly proteins, Interleukin-4 (IL4), Thyroglobulin (THYG) and 
Interleukin-2 (IL2) were significantly  less abundant in tumor samples with log2 fold change and 
adjusted p-value of (-2.15, 2.87e-13), (-1.87, 2.91e-33) and (-1.58, 2.61e-24) respectively. Two 
different antibodies representing TNFRSF10A were found significantly more abundant in the 
tumor samples which explain the high specificity and robustness of the antibody microarray. A 
table with the log2 fold changes and adjusted p-values of all the twenty significantly 
differentially abundant proteins is shown in the supplementary section (table S1). 
3.1.3 Differential expression of proteins between recurrent and non-recurrent 
non-muscle invasive bladder tumors 
To understand the proteins involved in recurrence of non-muscle invasive bladder cancers, 
twenty five tumor samples were analyzed with complex antibody microarrays. All the samples 
considered for analysis belonged to low grade and stage (Ta and T1) of tumor. Those patient 
samples only with a follow-up period of five years after the resection of primary tumors were 
considered for analysis. Tumors that recurred within five years post primary resection were 
considered recurrent group while those that did not recur within five years were considered to be 
cured of bladder cancer. Among the twenty five samples used in the analysis, nineteen samples 
had recurred within five years and six samples did not recur and were considered as a group of 
non-recurrent tumors or cured. Protein samples were isolated from all the patient tissues along 
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with three normal bladder tissues and were labeled in two fluorescent dyes Cy3 (DY-549) and 
Cy5 (DY-649). A common reference pool was made by pooling equal amount of protein from all 
the samples for normalization of the data and incubations of the individual samples were 
performed in presence of the reference pool for the same purpose. All the samples were 
incubated on the antibody microarray consisting eight hundred and thirteen antibodies directed 
against seven hundred and twenty four cancer related proteins. Incubations of random samples 
were performed in different days and time but without any technical and handling variations 
(figure 8).  
Among the seven hundred and twenty four antibodies detected in the array, two hundred and 
fifty five proteins were significantly differentially abundant among the recurrent and non-
recurrent group (table S2). A hundred and five proteins among the significantly differentially 
abundant were more abundant in recurrent tumors while remaining hundred and fifty were found 
lesser in abundance in the group. A hundred and two proteins among the two hundred and fifty 
five were very highly significantly differentially abundant with an adjusted p-value less than 
0.003. The results from the whole analysis were exhibited as a volcano plot most of the proteins 
named with the log fold change and adjusted p-values (figure 10). The individual protein 
expression variations were studied to assess the significance of findings from individual patients. 
A box plot was made for some of the proteins and is represented in figure 11. Lamin-A (LMNA) 
and transcription factor AP-1 (JUN) were the most abundant proteins in recurrent tumors while 
L-Selectin (LYAM1) and Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) were found with 
very less abundance in recurrent tumors (figure 11).  
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Figure 10. Volcano plot of differentially abundant proteins. Horizontally, the degree of 
expression variation is shown; the vertical axis indicates the significance level. The black dots 
represent the proteins that were analysed. The red line stands for an adjusted p-value of 0.003. 
All proteins located above this threshold are highly significantly informative about the 
recurrence status of a patient. Some particular proteins are named. 
 
 
Recurrence versus no-recurrence 
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Figure 11. Distribution of protein expression in all patient samples. Data are shown for proteins 
LMNA and JUN (up-regulated in non-recurrent tumours) as well as LYAM1 and CDN1A 
(down-regulated in non-recurrent tumours). 
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3.1.4 Accurate prediction of recurrence in non-muscle invasive bladder cancer 
by protein signature 
A multivariate analysis was performed to assess the prognostic capabilities of the highly 
significantly differentially abundant proteins. A rule for accurate classification of the samples 
was established based on random forest method (Breiman, 2001) combined with the twenty 
proteins that were most significantly differentially abundant. The training set was classified with 
100% sensitivity and specificity. Leave-one-out cross validations were performed to assess the 
efficient transferability of the classification to other test sets. The classification results for the 
different test sets in the cross validation steps were summarized as a receiver operating 
characteristics (ROC) curve (figure 12). The miss-classification rate for the cross-validation was 
20% (SD 0.08). Also the area under the curve (AUC) value of 0.91 exhibits the extremely high 
accuracy of discriminating between the patients with and with-out recurrence (figure 12). That 
corresponds to the overall sensitivity of 80% at 100% specificity. Twenty proteins that were 
highly significantly differentially abundant based on which the samples were classified is shown 
in table 1 along with their corresponding log fold change and adjusted p-value. A strong study on 
already published peer reviews connecting these twenty abundant proteins is also shown in the 
table 1. 
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Figure 12. Receiver operating characteristic (ROC) curves resulting from random forest 
classification. Discrimination within the trainings set was 100% (dotted line). Stringent leave-
one-out cross validation yielded an AUC value of 0.91 (black line). 
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Protein Uniprot 
entry name 
Uniprot 
accession 
Adjusted 
p-value 
Log fold 
change Reported studies 
LMNA_HUMAN P02545 3.3e-09 0.72 BC (Konstantakou et al., 2009; Stravopodis et al., 2009) 
YBOX1_HUMAN P67809 1.9e-08 0.52 RC C 
(To et al., 2010) 
(Gluz et al., 2009) 
JUN_HUMAN P05412 1.3e-07 0.50 
RBC 
BC 
RC 
(Mitra et al., 2009) 
(Ling et al., 2011) 
(Ouyang et al., 2008) 
AKT3_HUMAN Q9Y243 2.5e-07 0.48 BC RC 
(Ching and Hansel, 2010) 
(Bonin et al., 2008) 
YETS2_HUMAN Q9ULM3 5.2e-06 0.32 - No cancer related reference 
CADH1_HUMAN P12830 1.2e-05 0.33 RBC (Gallagher et al., 2008; Negraes et al., 2008) 
TIA1_HUMAN P31483 2.1e-07 -0.39 C (Alvaro et al., 2005) 
SMAD3_HUMAN P84022 2.1e-07 -0.58 C (Penuelas et al., 2009; Poncelet and Schnaper, 2001) 
PABP1_HUMAN P11940 2.1e-07 -0.36 C (van Duin et al., 2005) 
CDN1A_HUMAN P38936 3.4e-07 -0.52 RBC BC 
(Shariat et al., 2008) 
(Shariat et al., 2007) 
LYAM1_HUMAN P14151 9.6e-07 -0.51 C (St Hill, 2011) 
AKTIP_HUMAN Q9H8T0 5.4e-06 -0.34 C (Cinghu et al., 2011) 
PRI1_HUMAN P49642 1.0e-05 -0.35 C (Yotov et al., 1999) 
HSP7C_HUMAN P11142 1.0e-05 -0.34 - No cancer related reference 
RSSA_HUMAN P08865 1.1e-05 -0.35 C (Qiu et al., 2008) 
GRM1A_HUMAN Q96CP6 1.1e-05 0.28 C (Martino et al., 2012) (Speyer et al., 2012) 
TPA_HUMAN P00750 1.1e-05 0.23 BC (Louhelainen et al., 2006) (Knowles et al., 1993) 
ZBT17_HUMAN Q13105 1.1e-05 -0.54 C (Ikegaki et al., 2007)  (Iraci et al., 2011) 
LAMP2_HUMAN P13473 1.1e-05 0.26 C (Lee et al., 2012) (Tung et al., 2010) 
JUN_HUMAN P05412 1.3e-05 0.48 
RBC 
BC 
RC 
(Mitra et al., 2009) 
(Ling et al., 2011) 
(Ouyang et al., 2008) 
Table 1. List of the twenty proteins with the most significant expression variations between 
recurrent and non-recurrent tumours. Log fold changes in expression and the related adjusted p-
values are shown. Also, literature is listed in which the protein or respective gene was reported in 
connection with bladder cancer (BC), recurrence of bladder cancer (RBC), recurrence of other 
cancer forms (RC), or cancer overall (C). 
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3.1.5 Functional annotation of highly significantly abundant proteins 
The possible functional aspects between recurrence and non-recurrence of the samples were 
studied based on the functional studies on the significantly abundant proteins using a web-based 
analysis platform DAVID (Huang da et al., 2009). About 56% proteins among the highly 
abundant in recurrent tumors were expressed inside the cells while 61% of the proteins among 
those that were less abundant were secreted by the cells or expressed in the extracellular space. 
Web-based pathway analysis program KEGG (Kanehisa et al., 2012) showed a strong 
suppression in the TGF-beta signaling pathway in the recurrent cancer when the significant 
proteins were tested using the program (figure 13). The expression of important factors like 
INFG, TNFA, TGFB and THBS1 was less in recurrent samples while inhibitor of MAPK3 
(known as ERK1) was highly abundant and again Mothers against Decapentaplegic Homolog 
proteins like SMAD1, 2 and SMAD3 were significantly less abundant in recurrent samples. 
Transcription factor SP1, an important downstream signaling protein was also less abundant in 
recurrent samples. Along with TGFB pathway, proteins involved in apoptosis were also strong 
regulated. Among those more abundant proteins in recurrent samples were effectors Caspase 3 
(CASP3) and 9 (CASP9), both in their active form and the regulator Bcl2 associated –X (BAX) 
(table S2).  Interestingly, the Trail-receptor which could active all the above proteins was also 
high in abundance in recurrent samples. On the other hand, FAS was less abundant in recurrent 
samples. Similarly some of the transcription factors previously studied in carcinogenesis and 
more widely in other diseases were also differentially abundant in recurrent samples. Variations 
in regulation of most of the cancer related proteins in cancer pathways were colored and given as 
a supplementary (figure S1, S2). 
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Figure 13. K
EG
G
 analysis of the TG
F-beta signalling pathw
ay. A
ffected proteins are labelled in green or red 
if their expression w
as low
er or higher, respectively, in recurrent rather than non-recurrent cancer. 
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The pathways in signaling and cancer from KEGG analysis most often highlighted those proteins 
involved in apoptosis and cell proliferation. This fact was also identified by the studies on gene 
ontology as functions of many abundant proteins in recurrent samples were representing both 
pro-apoptotic and anti-proliferative effects. In addition to pathways and analysis of proteins 
based on their ontology, important proteins like transcription factors, cell cycle regulators, those 
among the abundant proteins were also analyzed by web-based protein-protein interaction 
software STRING 9.1 (Szklarczyk et al., 2011). Among the highly abundant proteins in recurrent 
tumors, transcription factor AP-1 (JUN), Nuclear factor NF-kappa B1 (NFκB1), DNA Topo 
isomerase-2 alpha (TOP2A), Krueppel-like factor (KLF5) and Cadherin-1 (CDH1) were 
interacting among each other by protein-protein binding and activation of expression (figure 14). 
The less abundant proteins in recurrent tumors like Mothers against Decapentaplegic Homolog-3 
(SMAD3), Matrix Metalloproteinase-1 (MMP1), Tissue Inhibitor of Metalloproteinases 1 
(TIMP1), Vascular Endothelial Growth Factor A (VEGFA) and transcription factor SP1 were 
reported to interact among each other by activation, inhibition and binding (figure 14). Among 
the interactions, JUN a highly abundant protein was studied earlier to inhibit TIMP1, a less 
abundant protein in recurrent tumors. Similarly, many such interactions were reported from the 
analysis and studied vastly through peer reviewed publications.    
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Figure 14. Protein interactions of strongly regulated proteins. Analysis of the protein expression 
data with the pathway analysis software STRING 9.1 revealed several protein interactions. 
Proteins coloured in red were higher expressed in recurrent than non-recurrent tumours; green-
coloured proteins exhibited lower expression.  
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3.2 Protein biomarker identification in Gastric adenocarcinoma 
3.2.1 Hierarchical clustering of samples after normalization 
In the current study, the protein samples from normal gastric tissues and high stage and grade 
gastric adenocarcinoma tissues were compared for the identification of protein biomarkers for 
effective diagnosis and prognosis. The samples were analyzed using antibody microarrays 
constructed as mentioned in sections 2.2.4(1, 2 and 3) in methods. To also study the consistency 
of the expression, all samples were incubated in duplicates on the arrays. The samples were 
incubated on the antibody microarrays in a single batch to minimize the technical artifacts that 
may arise. An unsupervised clustering of the samples was done after normalization of the data. 
In the hierarchical cluster, the samples were found clustered according to the type of the tissue 
(figure 15). All the duplicates N,DN and T,DT were clustered together in the hierarchical cluster 
(figure 15) referring to the presence of no technical artifacts such as handling, position of the 
slides in slidebooster and incubation of samples on different arrays itself. These results suggested 
that the clustering and segregation of normal and tumor samples were only based on the 
differential abundance of proteins in them and not any other artifacts. After normalization the 
data were analyzed for differential abundance of proteins. 
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Figure 15. Hierarchical cluster analysis of the sample set. The Euclidean distance and the 
average linkage method were used. The samples names are given, normal (N, DN) and tumor (T, 
DT). The incubation was done on the same day. The duplicates of the samples were clustered 
apart from the cluster groups of normal and tumor groups. 
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3.2.2 Differential expression of proteins between normal gastric tissues and 
gastric adenocarcinoma tissues 
To identify protein biomarkers for effective diagnosis of gastric adenocarcinoma, twenty five 
surgically removed tumor tissue samples along with adjacent normal tissue samples from 
patients diagnosed with gastric adenocarcinoma were analyzed with complex antibody 
microarrays. All the samples considered for analysis belonged to high grade and stage (T3 and 
T4) of tumor. Those patient samples only without prior treatment for gastric cancer were 
considered for analysis. Among the twenty five pair (normal and tumor) of tissues used in the 
analysis, ten pairs were considered as training set and fifteen pairs were considered as test set. 
Protein samples were isolated from all the tumor and normal tissues and were labeled in two 
fluorescent dyes Cy3 (DY-549) and Cy5 (DY-649). For incubations of the training set of 
samples, a common reference pool was made by pooling equal amount of protein from all the 
samples for normalization of the data and incubations of the individual samples were performed 
in presence of the reference pool for the same purpose. The test sets were incubated separately 
by swapping the dyes labeled and nature of the samples and vice versa. All the samples were 
incubated on the antibody microarray consisting eight hundred and thirteen antibodies directed 
against seven hundred and twenty four cancer related proteins.  
3.2.2.1 Differential expression of proteins- training set of samples  
Among the seven hundred and twenty four antibodies detected in the array, eight proteins were 
significantly differentially abundant between normal and tumor samples (table 2). Three proteins 
were significantly differentially more abundant in tumor samples while remaining five proteins 
were found lesser in abundance. These proteins were very highly significantly differentially 
abundant with an adjusted p-value less than 0.04 (table 2). A heat-map featuring the eight highly 
 
Results 
 
 
52 
 
differentially abundant proteins is represented in figure 16. Nucleolysin-TIA1 (TIA1) was found 
highly significantly differentially more abundant in the tumor samples with a log fold change of 
1.19 and an adjusted p-value of 0.04. While, Mucin-6 (MUC6) was found very less in abundance 
in tumor samples with a very high significance (log fold change -2.45 and adjusted p-value 9e-
06). Gamma-Enolase (ENOG), Epidermal growth factor (EGF) and Folate receptor alpha 
(FOLR1) were also among the highly regulated proteins (figure 16). 
 
 
 
 
 
 
Table 2. List of the eight proteins with the most significant abundance between normal and 
tumor samples in the training set. Log fold changes in expression and the related adjusted p-
values are shown.  
 
 
Protein Uniprot 
entry name 
Uniprot 
accession 
Adjusted p-
value 
Log fold 
change 
EGF_HUMAN P01133 0.04 -0.30 
ENOG_HUMAN P09104 0.02 0.28 
IRS2_HUMAN Q9Y4H2 0.03 -0.26 
MPIP2_HUMAN P30305 0.04 -0.24 
FOLR1_HUMAN P15328 0.04 0.53 
GBRB1_HUMAN P18505 0.04 -0.28 
MUC6_HUMAN Q6W4X9 9e-06 -2.45 
TIA1_HUMAN P31483 0.04 1.19 
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Figure 16. Heat map of proteins with significant differential abundance in normal and tumor 
samples (also in duplicates). Highly abundant proteins were represented in red while proteins 
with less abundance were represented in blue. Only proteins with an adjusted p-value less than 
0.05 were represented in the heat map. The sample set here is considered to be the training set. 
3.2.2.2 Differential expression of proteins- test set of samples  
Incubations of fifteen pairs (normal and tumor) samples were carried out by dye swap method. 
Normal sample labeled with Cy3 from a patient is incubated with tumor sample labeled with Cy5 
from the same patient. Alternatively, duplicates from the same samples were incubated in the 
opposite manner by labeling tumor samples in Cy3 and normal samples in Cy5. Similar steps 
were followed for incubations of all the thirty samples. Among the seven hundred and twenty 
four proteins detected in the array, ninety one proteins were found significantly differentially 
abundant between normal and tumor samples, out of forty two proteins were more abundant in 
tumor samples and forty nine proteins were less abundant in them. About sixteen proteins were 
highly significantly regulated with an adjusted p-value less than 0.03. Many differentially 
abundant proteins among the training set samples were also found differentially abundant in the 
test set samples. Among the most significantly abundant proteins, Calgranulin B (S100A9), 
Insulin-like growth factor-binding protein 7 (IGFBP7) and Calponin-2 (CNN2) were found more 
abundant in tumor samples while Mucin 6 (MUC6) was less in abundance in tumor samples. 
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Protein Uniprot 
entry name 
Uniprot 
accession 
Adjusted p-
value 
Log fold 
change 
AQP_HUMAN P29972 0.002 1.74 
CD27_HUMAN P26842 0.02 3.45 
CNN2_HUMAN Q99439 1.4e-07 1.84 
ENOG_HUMAN P09104 0.03 1.04 
IBP7_HUMAN Q16270 6.13e-06 2.02 
IFNG_HUMAN P01579 0.004 1.74 
IL10_HUMAN P22301 0.002 2.77 
ITA5_HUMAN P08648 0.002 2.21 
OCLN_HUMAN Q16625 0.03 0.57 
S10A9_HUMAN P06702 2.31e-05 2.01 
TFPI2_HUMAN P48307 0.01 2.51 
TIA1_HUMAN P31483 0.001 0.67 
VEGFA_HUMAN P15692 0.002 2.88 
CKS2_HUMAN P33552 0.004 -1.83 
DKK3_HUMAN Q9UBP4 0.03 -0.85 
MUC6_HUMAN Q6W4X9 1.88e-07 -3.71 
 
Table 3. List of the top sixteen proteins with the most significant abundance between normal and 
tumor samples in the test set. Log fold changes in expression and the related adjusted p-values 
are shown. Three proteins (colored green), ENOG, TIA1 and MUC6 were found significantly 
differentially abundant in both the training and test sets of samples.  
Three proteins found highly regulated in the training set samples were also found among the 
highly differentially abundant proteins in tumor samples of the test set. ENOG and TIA1were 
found more abundant among the highly regulated proteins in the test set samples while MUC6 
was found less abundant in them. Most significantly differentially abundant proteins were listed 
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along with their log fold change and adjusted p-values in table 3. The results from the whole 
analysis were exhibited as a volcano plot most of the proteins named with the log fold change 
and adjusted p-values (figure 17).  
 
Figure 17. Volcano plot of differentially abundant proteins. Horizontally, the degree of 
expression variation is shown; the vertical axis indicates the significance level. The black dots 
represent the proteins that were analysed.  The pink dot represents TIA1 which was also found 
differentially abundant in the training set. Some other particular proteins are named. 
Cancer versus healthy controls 
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The individual protein expression variations were studied to assess the significance of findings 
from individual patients. To test differential abundance of proteins and specificity of their 
regulation in normal and tumor tissues, a western blot analysis was carried out. Two protein 
pools were made by random selection of normal and tumor samples. These two pools of normal 
(Normal 1 and 2) and tumor protein (Tumor1 and 2) were resolved in 10% and 15% SDS-poly 
acrylamide gels and transferred to nitrocellulose membranes as mentioned early in methods 
section 2.2.2.4. Antibodies against human TIA1 and S100A9 were incubated on the membranes 
to detect the expression of respective proteins in normal and tumor samples. Antibody against 
human glyceraldehyde-3-phosphate dehyrogenase (GAPDH) was used as a loading control. The 
differential abundance of these proteins is exhibited visually in figure 18a and 18b.  
       
Figure 18. Immunoblot analysis of expression of proteins TIA1 and S100A9. Normal 1 and 2 
are pools of proteins made by pooling random normal samples. Tumor 1 and 2 are pools of 
proteins made by pooling random tumor samples. Anti-GAPDH conjugated with horse-radish 
peroxidase against human is used as a loading control. a) TIA1 found more abundant in tumor 
samples as compared to normal. b) S100A9 was also found in more abundance in tumor samples 
as compared to normal.  
 
a) b) 
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4 Discussion 
4.1 Cancer biomarkers identification by antibody microarrays  
 Cancer as a disease is too difficult to manage as it is life-threatening when it affects many vital 
organs in humans. There is a need for early and non-invasive diagnosis of the disease in one 
hand and to minimize the patient’s psychological and financial stress on the other. An effective 
diagnosis will provide ways to not only reduce the false positive cases but also the strategies for 
effective therapy (Hartwell et al., 2006). Gold standard diagnostic methods using both genomic 
and proteomic methods were studied and developed extensively in the past decade. Proteomics 
as it deals with proteins, the biological end-product and acting-product in a complex system 
provided further more details in the mechanics of disease occurrence and recurrence (Alhamdani 
et al., 2009). Two-dimensional gel electrophoresis and Mass-spectrometry were two proteomic 
methods, extensively used with vast limitations on sensitivity and reproducibility and 
optimization.  
The use of complex affinity protein-array technologies improved the limitations with other 
proteomic methods and increased the relevance of underlying molecular mechanisms such as 
protein-protein interactions, binding and activation of expression etc. (Alhamdani et al., 2009). 
These systems not only improve the specificity, sensitivity and robustness but also operate with 
minute probe and sample requirements mostly in picolitre and femtolitre (Alhamdani et al., 
2009). Like DNA microarrays, the antibody microarrays were also printed on a solid support 
(often microscopic slides) coated with chemical binders on the surface (Wingren et al., 2007). 
Antibody microarrays being a novel technology have evolved from very less number of probes 
being used (between twenty and two hundred previously) to large numbers (eight hundred in our 
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case) (Schroder et al., 2010; Wingren et al., 2007). Experimental procedures like sample 
preparation, labeling and incubation procedures were optimized regularly (Alhamdani et al., 
2009; Alhamdani et al., 2010).  The selection of antibodies is based on the previous results from 
other high-throughput techniques with a vast coverage of previous studies on cancer biomarkers 
identification. Cancers often studied are pancreatic, breast and colon in comparison to their 
respective healthy controls. Eight hundred and ten antibodies raised against seven hundred and 
forty one cancer-related proteins are spotted on glass slides coated with epoxysaline. Six hundred 
and sixty eight affinity-purified polyclonal antibodies from rabbit were provided by Eurogentec 
and other hundred and forty two were purchased commercially and provided by collaborating 
partners. All these antibodies are immobilized on the slide surface in duplicates for consistency 
of the results. 10 µg of antibody is used for producing 1000 microarrays which is much lesser 
than the amount spent on various ELISA experiments. In case of two dimensional gel 
electrophoresis, samples are denatured and iso-electrically separated for an effective analysis. 
Furthermore, samples are depleted in mass-spectrometry experiments. Samples incubated on the 
antibody microarrays are maintained in their native state (Alhamdani et al., 2009; Schroder et al., 
2010). All these advantages provide more native and specific at the same time sensitive analysis 
of samples (Alhamdani et al., 2009; Schroder et al., 2010). 
Above all, as mentioned earlier, the whole method deals with proteins, the biological end-
product. Therefore, it seems that antibody microarrays can be implemented in effective 
biomarker identification for diagnosis and therapy of various cancers at proteome level. In 
reference to the above claims, two cancers (bladder and gastric) were analyzed using above 
developed antibody microarray.  
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4.2 Non-muscle invasive bladder cancer 
 Non-muscle invasive bladder cancer, being a low grade, low stage tumor with high probability 
of recurrence is very important to study as the prognosis and prediction of recurrence can have 
several clinical consequences.  The current study uses complex antibody microarrays to look out 
for molecular variations to predict recurrence at protein level since they are responsible for most 
of the cellular activities and thus representing the best functionality relevant differences. Many of 
the earlier studies used body fluids from both low and high grade tumors for an effective 
diagnosis and prognosis of the disease in patients with bladder cancers. Some of them even 
implemented proteomic methods. Antibody microarrays were implemented to profile serum 
samples from bladder cancer patients (Sanchez-Carbayo et al., 2006). The study revealed not 
only the differentiation of healthy and cancer patients but also a four protein signature to separate 
patients into high and low risk groups. The study used mere hundred and fifty antibodies on the 
array which were previously studied in bladder cancers. A mass-spectrometry based study was 
done by analyzing the urine samples of patients diagnosed with muscle invasive bladder cancer 
(Schiffer et al., 2009). The analysis could predict muscle invasive bladder cancer with a 
sensitivity of 92% and specificity of 68%.  
Most of the proteomic-based studies in bladder cancers were concerned with both low and high 
grade cancers, while we focus only on the low grade and low stage cancers. Another interesting 
aspect of our study is the follow-up time. Although a five-year follow-up limited the sample size, 
we insisted on it as the recurrence history of most of the studied non-muscle invasive bladder 
tumors were within five years of the follow up. The proteome analysis is carried on the proteins 
from the tissue extracts of primary tumors diagnosed with non-muscle invasive disease since 
patient prognosis depends strongly on the likelihood of local recurrence. As regular transurethral 
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resections of tissues are performed upon during initial diagnosis of the cancer, enough patient 
material was available for the whole analysis. 
4.2.1 Differential expression of proteins between recurrent and non-recurrent 
non-muscle invasive bladder tumors 
The current study on non-muscle invasive bladder cancers with long term follow-up on 
recurrence identifies two hundred and fifty five proteins (figure 10) with significant differential 
abundance which is surprising as most of the target proteins were selected on the basis of studies 
from different cancers in comparison to their related healthy tissue. High number of proteins 
regulated between two tumor types is very interesting to study along with their functional 
annotation. These very high numbers of variations in proteins levels indicate massive differences 
in the biology of recurrent and non-recurrent tumors. As proteins prominently studied in bladder 
cancers are also differentially regulated, the results are easy to compare with the available 
literature and to identify new biomarkers along with the already studied ones (table 1). More 
importantly, many such proteins those are significantly differentially more abundant in recurrent 
tumors are known key players in vital functions in oncogenesis. At the same time, many 
abundant proteins were either studied vastly in high grade bladder cancers or other cancers as 
potential therapeutic targets. These previous studies strongly encouraged carrying on further 
bioinformatics analysis on pathways involved, interactions and disease related modifications. 
Proteins, JUN, TOP2A and NFκB1 were often studied in various types of cancers. The top 
twenty significantly differentially abundant proteins were tabulated with some of their 
respectively studied literature (table 1).  
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Among the significantly highly abundant proteins in recurrent tumors, JUN, a well known 
transcription factor and a proto-oncogene was extensively studied previously. Elevated levels of 
JUN had been identified as a prognostic marker for high risk and recurrence of prostate cancer 
(Ouyang et al., 2008). Few studies in transcriptional level in different cancers also identified 
JUN as a prognostic factor for high risk and disease progression. A transcriptional analysis to 
predict survival and recurrence in bladder cancer samples identified a four-transcript signature 
including JUN. The analysis also predicted bad outcome in correlation with high abundance of 
JUN (Mitra et al., 2009). The knockdown of phospholipase Cε affected the expression of JUN, in 
turn negatively regulating the proliferation of BIU-87 bladder cancer cells (Ling et al., 2011).  
Among the significantly less abundant proteins in recurrent tumors, SP1, a transcription factor 
that binds to gc-rich motifs with high affinity to regulate the expression of vital genes involved in 
cell growth, apoptosis and differentiation was well studied in high grade cancer including muscle 
invasive bladder cancer. SP1 was identified as a potential therapeutic target in high grade high 
stage muscle invasive bladder cancers. Small drug molecules targeting specificity proteins (SP1, 
SP2 and SP3) decreased their expression, inhibited the cell proliferation and tumor cell growth in 
muscle invasive bladder cancers (Chadalapaka et al., 2010; Chadalapaka et al., 2008; Jutooru et 
al., 2010). It is quite fascinating that the abundance of two transcription factors already studied in 
bladder cancers appeared differently in the current study. The studies from literature correlate 
with their abundance in recurrent non-muscle invasive tumors. From the above studies, one can 
hypothese that different mechanisms by transcription factors JUN and SP1 account for 
recurrence and progression of non-muscle invasive bladder respectively. The current study any 
way is not detailing the functional aspects of the differentially abundant proteins.  
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4.2.2 Apoptotic proteins and recurrent non-muscle invasive bladder cancers 
Interestingly, pro-apoptotic proteins like active or cleaved CASP3, CASP9 and BAX are found 
more abundant in the recurrent non-muscle invasive bladder cancers (figure 10). CASP3 levels 
were known to be low in high grade muscle invasive bladder cancers (Karam et al., 2007). In 
other cancer entities, CASP3 over-expression was associated with recurrence and high cancer 
mortality rates (Huang et al., 2011; Jonges et al., 2001; Konstantinidou et al., 2007). CASP3, a 
cysteine-aspartic acid protease that activates a cascade of pro-apoptotic proteins and in turn 
apoptosis, is also known for its non-apoptotic roles such as differentiation, dedifferentiation and 
activation of immune cells (Fujita et al., 2008; Kennedy et al., 1999; Szymczyk et al., 2006). 
Active CASP3 had been reported as a prognostic marker in colorectal cancers with combined 
activation and over- expression of CD57 (Jonges et al., 2001). The increase in recurrence of 
apoptotic tumors after radio or chemotherapy was illustrated by the ability of active CASP3 to 
repopulate tumor cells through prostaglandin E2 (Huang et al., 2011). Apoptotic tumor cells 
leads to an increase in the levels of arachidonic acid in the extracellular space through CASP3-
mediated calcium-dependent phospholipase A2 (iPLA2) activation. This activates of 
prostaglandin E2 through prostaglandin synthase H (PGH2), a downstream product of 
arachidonic acid and is known to be a key regulator of tumor growth. Apart from the above 
observations, Huang et al could also correlate higher levels of active CASP3 with high 
occurrence of tumor recurrence in head and neck squamous cell carcinoma and breast carcinoma 
which also supports our observations. The current study identifies both active form of CASP3 
and CASP9 along with PGH2 more in abundance in the recurrent non-muscle invasive tumors. 
As the pattern of abundance correlate with the above observations, it can be proposed that a 
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similar mechanism of active CASP3 apoptosis-mediated tumor cell repopulation via PGH2 is 
seen also in recurrence of non-muscle invasive bladder cancers.  
4.2.3 Functional annotations by pathway analysis and interactive studies 
Apart from the apoptotic-regulatory proteins, a detailed functional annotation on the significantly 
differentially abundant proteins reveals a strong inhibition in the TGFβ signaling pathway in the 
recurrent non-muscle invasive tumors. The activators of the signaling pathway like IFNγ, TNFα, 
TGFβ and SMAD family of proteins along with transcription factor SP1 are found less abundant 
in recurrent tumor samples, while on the other hand MAPK3 ( also known as ERK1) is high in 
abundance (figure 13). Similar repression of TGFβ/SMAD signaling were previously observed 
in different cancer entities and the repression was strongly associated with either a high risk for 
recurrence of the disease or a poor outcome (Alazzouzi et al., 2005; Xie et al., 2003). Further 
detailed analysis using online bioinformatics tools like KEGG, DAVIDGO and STRING 9.1 
provide more insights on protein interactions and activation or repression of expression (figure 
14). Among the highly significantly more abundant proteins in recurrent tumors, the interactions 
among JUN, NFκB1, KLF5, TOP2A and CDH1 are extensively reported in studies on 
oncogenesis and other disease conditions. TOP2A, a nuclear enzyme involved in processes such 
as chromosome decondensation, chromatid separation and relief of torsional stress that occurs 
during transcription and replication of DNA was observed to interact directly with JUN which 
increases the decatenation activity of TOP2A on DNA (Kroll et al., 1993). JUN was also 
observed to interact with NFκB1, a transcriptional regulator that is activated by various intra- 
and extra-cellular stimuli like cytokines, oxidant-free radicals and viral products. When 
activated, NFκB1 is translocated into the nucleus to stimulate the expression of genes involved in 
a wide variety of biological functions. The interaction between JUN and NFκB1 in endothelial 
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cells was exhibited to regulate the expression of vascular cell adhesion molecule-1 (VCAM1). 
This activation is an important feature of the initial steps of pathogenesis in atherosclerosis 
(Ahmad et al., 1998). KLF5, a transcription factor that binds to gc box promoter elements, 
localized to the nucleus binding the EGF response element was observed interacting with 
inflammatory response element NFκB1. Platelet derived growth factor-A (PDGFA) gene 
expression was exhibited to be activated by the interaction of p50 subunit of NFκB1 and KLF5. 
The interaction forms a protein complex on the binding site of KLF5 on the promoter chains of 
PDGFA (Aizawa et al., 2004). CDH1, a calcium dependent cell-cell adhesion glycoprotein 
whose loss of function is associated with cell proliferation and invasion is inhibited by NFκB1. 
NFκB1 is observed to suppress the expression of CDH1and induce the expression of vimentin, a 
mesenchymal specific gene. This induction leading to the epithelial to mesechymal transition of 
mammary cells is exhibited in breast cancers (Chua et al., 2007).  
Significantly less abundant proteins in recurrent non-muscle invasive tumors are observed 
interacting among themselves, especially proteins such as SP1, SMAD3, VEGFA and TIMP1 are 
often reported in previous studies on cancer entities (figure 14). VEGFA, a growth factor 
activating angiogenesis and endothelial cell proliferation interacted with SP1 in pancreatic 
adenocarcinoma cells through IRS2, a downstream molecule of IGF 1 receptor signaling 
pathway. This activation of expression of VEGFA by SP1 causes pancreatic cancer cell 
proliferation (Neid et al., 2004). Induction of VEGFA expression by SP1 when associated with 
P38 kinase was also observed in cardiomyocytes (Lin et al., 2011). TIMP1 expression was 
effected by SP1 in human embryonic kidney cells which leads to uncontrolled proliferation of 
them (Lee et al., 2004). Combined over-expression of SMAD3 and SP1 in glomerular cell 
cancers induced the promoter activity of α2 (I) collagen gene (COL1A2) that lead to the 
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activation of TGFβ signaling pathway (Poncelet and Schnaper, 2001). These interactions 
reported and observed in various disease conditions explain their biological significance and 
vitality in not only onceogenesis but also general growth regulating mechanisms. It can be easily 
conceivable that interactions among both highly abundant and less abundant proteins in recurrent 
non-muscle invasive tumors are directly or indirectly responsible for disease recurrence or 
progression.  
4.2.4 Recurrence prediction in non-muscle invasive bladder cancers 
The current study reveals a 20 protein signature to predict the recurrence of cancer with very 
high accuracy (figure 12). The available methods for prediction of recurrence appear to be very 
inferior to the high accuracy in sensitivity and specificity of this 20 protein signature. The protein 
signature could predict recurrence with 80% sensitivity and 100% specificity as compared to the 
available approved NMP22 assay for bladder cancer diagnosis (Grossman et al., 2005) which 
exhibits a sensitivity of merely 55.7% and a specificity of 85.7%. Though, the number of 
samples analyzed appears to be very less for such a claim, the five year follow-up time appears 
clinically significant. The sample limitations can also be rectified by some non-invasive analysis 
on body fluids as most of the proteins in the signature are known to be secreted. The gold-
standard diagnostic methods in clinical settings including immuno-histo chemistry are all 
immuno-based assays. Antibody microarray, as itself is an immuno-based assay has the great 
potential to be used in clinical situations. Furthermore, these marker proteins can be translated 
easily to standard immuno-based assay platforms that are routine in use in clinical settings. On a 
broader outlook, such a test for prediction of recurrence can adjust the treatment regimen and 
rigidity of surveillance, especially in bladder cancers where patients were followed up for years 
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using cytoscopy methods. This can not only reduce surveillance costs but also improve the 
patients’ outcome substantially.   
4.3 Biomarker identification for gastric adenocarcinoma by 
antibody microarrays 
Far too many studies emphasize the role of different regulators of cell cycle, cell growth, 
proliferation, angiogenesis and apoptosis in gastric cancer formation and evaluate their potential 
as a valuable therapeutic target. Various methods are being employed to study the molecular 
basis of gastric adenocarcinoma, but only few evolve till the treatment strategies. Despite recent 
developments in high-throughput methods like signature based molecular diagnostics, mass 
spectrometry (MS) based proteomic methods and next generation sequencing, availability of 
suitable biomarkers at protein levels often, is disappointing. Either occurrence of high false 
positive cases or controversial published data on the role of molecular markers restricts, not only 
the implementation of many markers but also fails to address the response due to inter-individual 
variability (Pietrantonio et al., 2013). DNA microarray, as a powerful high-throughput technique 
only identifies novel genes which as biomarkers, fail at protein level when conventional 
immuno-based assays such as immuno-histochemistry (IHC) and ELISA were used (Zheng et al., 
2004). Advances in large-scale gene expression profiling combined with network analysis 
identified several biomarkers without much clinical relevance on the stage dependent expression 
of the genes. Moreover, these markers do not predict the progression and patient outcome which 
is again important for an optimal treatment strategy (Takeno et al., 2008). Apart from DNA and 
RNA microarrays, tissue microarrays are good tools for protein level biomarker identification 
with much limitations in number of molecules studied (Senapati et al., 2008). Individual analysis 
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on cytotoxic molecules predicts acute gastric mucosal lesions (Suzuki et al., 2003). Similar 
analysis on other molecules involved in key biological processes, showed their significance as 
prognostic indicators in gastric adenocarcinomas but with much inconsistence disallowing them 
from being recognized as standard biomarkers (Kodama et al., 2008; Leung et al., 2004). So far, 
only antibody microarray based study on gastric adenocarcinomas deals with cancers associated 
with Helicobacter pylori infection. The study composed of mere hundred and twenty seven 
antibodies against immunoregulatory antigens. Apart from identifying plenty of previously 
reported proteins, the analysis also identified protein signatures associated with tumors and 
bacterial infection (Ellmark et al., 2006).  
We used complex antibody microarrays with eight hundred and ten antibodies described earlier 
(section 4.1) to analyze high grade, high stage (most even had lymph node metastasis) gastric 
adenocarcinoma samples. To get more insight on a personalized treatment strategy point of view, 
gastric adenocarcinoma tissues along with healthy tissue controls from the same patients are 
analyzed. The analysis comparing twenty five healthy controls with same number of gastric 
adenocarcinomas (both training and test sets) reveals several interesting candidates. 
4.3.1 Differentially regulated proteins in gastric adenocarcinoma 
Two different analyses on different sample sets identify ninety eight significantly differentially 
abundant proteins between cancer and healthy controls (table 2, 3 and figure 16, 17). Along with 
a lot of newly observed proteins, few proteins already described in gastric oncogenesis are 
identified from the analysis. Interestingly, five proteins are differentially abundant in both the 
training and test set of samples among which three are in the most significantly abundant 
proteins (table 3). Strikingly, proteins involved among highly invasive cancers including gastric 
adenocarcinomas are also present among the significantly abundant proteins. These results 
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triggered our interest for further analyses on the proteins with literatures. Proteins like AQP1, 
CNN2, TIA1, OCLN, S100A9, VEGFA and DKK3 best described oncogenesis.  
AQP1 
Aquaporin 1 (AQP1), a water channel protein facilitates water flux across cell membranes is 
found highly significantly more abundant in gastric adenocarcinoma tissues. Belonging to a 
family of small integral membrane proteins, they physically resemble channel proteins and 
highly abundant in erythrocytes and renal tubes. Also found in abundance in epithelial and 
endothelial cells, they are associated with cell migration, metastasis and angiogenesis. It is 
previously reported to be over-expressed in various human malignancies (Hu and Verkman, 
2006). AQP1 is proposed as a biomarker of early diagnosis of renal cancer on the analysis of 
urine samples from patients with renal cancer (Morrissey et al., 2010).  AQP1 in protein level is 
a poor prognostic factor in basal-like breast carcinomas as occurrence of death in patients 
suffering from breast cancers directly correlated with the high abundance of AQP1 (Otterbach et 
al., 2010). To our interest, this protein is not previously reported in gastric adenocarcinomas. 
CNN2 
Calponin 2 (CNN2) plays a role in smooth muscle contraction and cell-cell adhesion. It is found 
highly significantly more abundant in gastric cancer tissues. CNN2 is known to bind to actin and 
other channel proteins; for example, a calcium channel protein called calmodulin and involves in 
the structural organization of actin filaments. Other known functions of this protein include 
wound healing and positive regulation of cell proliferation. CNN2 being highly abundant in 
rectal cancers is proposed as a diagnostic biomarker at transcript level (Choi et al., 2011). CNN2 
is only reported in transcript levels in gastric cancers. 
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TIA1 
Nucelolysin TIA1 (TIA1), also called as T-cell intracellular antigen is an mRNA binding protein 
is expressed when cells undergo specific stress. They involve in both transcriptional and post-
transcriptional gene expression in eukaryotic cells. They activate nucleolysis against cells that 
target cytotoxic lymphocytes. Over expression of TIA1 under various stress conditions is studied 
in different human cells (Dinh et al., 2013; Gottschald et al., 2010). An important function of 
TIA1 is to regulate alternative pre-mRNA splicing of approximately 15% of the cassette human 
exons. High lethality rates in mice lacking TIA1 also shows their importance in regulation of 
important genes. Interestingly, TIA1 is not studied well in gastric cancers except inconsistent 
reports on abundance in protein level but in cancers like, colon, ovary and lymphoma TIA1 is 
found high in abundance (Izquierdo et al., 2011).  
OCLN 
Occludin (OCLN) found high in abundance in gastric adenocarcinoma is a protein known for its 
localization in tight junctions of both epithelial and endothelial cells. Over-expressing OCLN in 
cells lacking tight junctions induces cell adhesion. Mutations involved in OCLN gene leads to a 
rare neurological disorder called pseudo-TORCH syndrome. Belonging to the claudin family of 
proteins, OCLN is associated with epithelial-mesenchymal transition in colorectal cancers, which 
is one of the initial mechanisms in oncogenesis. It if found that OCLN is regulated by 
transcription factor AP4 which is a strong prognostic factor in colorectal cancers (Jackstadt et al., 
2013). In skin cancers, it is observed that OCLN is involved in Calcium ion-dependent 
homeostasis and other important cellular processes in oncogenesis like apoptosis, adhesion and 
differentiation (Rachow et al., 2013). One of the earlier studies on the expression of OCLN in 
esophageal, colon and gastric tissues found OCLN’s localization in the tight junctions of the 
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polarized epithelial cells. Further investigation with immuno-histochemical methods exhibited 
the expression of two tight junction proteins, OCLN and Zonula occludens (ZO1) in the highly 
differentiated tumor epithelia of colon and gastric cancers (Kimura et al., 1997). Gastric cancer 
cells in response to epidermal growth factor (EGF) treatment translocated OCLN from cytoplasm 
to the tight junctions which explain the role of it in cell-cell adhesion (Yoshida et al., 2005). 
From these results we suggest that OCLN is involved by similar mechanisms of oncogenesis in 
gastric adeonocarcinomas. 
S100A9 
S100A9 also known as calgranulin-B belongs to S100 family of calcium binding proteins 
localized mostly in the cytoplasm and nucleus. S100A9 is often studied in cancers for its 
properties other than calcium binding like apoptosis, cell cycle progression and differentiation. It 
also plays a role as a pro-inflammatory mediator in acute chronic inflammation. S100A9 is 
highly abundant in gastric cancer cells in the transcript level (El-Rifai et al., 2002). Apart from 
gastric cancers S100A9 is reported to be highly abundant at protein level in ovarian, hepato-
cellular and breast cancer. Interestingly, S100A9 is highly abundant in both malignant epithelial 
and stromal cells in high grade gastric adenocarcinoma leading to their detection in plasma 
samples of gastric cancer patients (Wang et al., 2013). It is not so surprising that S100A9 triggers 
cascade of signaling molecules including p38 mitogen-activated protein kinase and NFκB 
leading to the migration of gastric cancer cells and in turn  invasiveness of the gastric 
adenocarcinoma cells (Kwon et al., 2013). 
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VEGFA 
Vascular endothelial growth factor A (VEGFA) is a protein with all great potential functions 
involved in oncogenesis such as enhancing endothelial cell proliferation, promoting cell 
migration and inhibition of apoptotic signals. It is not only a growth factor with great abilities but 
also an active protein in vasculogenesis, endothelial cell growth, angiogenesis and promotes 
permeability of blood vessels. Such a protein is often a therapeutic target in many cancers and 
other diseases also. High abundance of VEGFA combined with SP1 at protein levels is directly 
correlated with the grade and stage of gastric adenocarcinomas. This co-expression resulted in 
poor prognosis of the disease (Yao et al., 2004). Metastasis and migration abilities of gastric 
adenocarcinoma cells are inhibited strongly when integrin alpha v beta 6 (IAVB6) function is 
lost. VEGFA is known to activate the integrin molecule IAVB6 which strongly suggests the 
therapeutic importance of drugs inhibiting VEGFA (Zhao et al., 2010). Another interesting study 
involving protein kinase D2 (PKD2) and VEGFA in gastric cancer cells finds the importance of 
the role of VEGFA in endothelial cell proliferation and migration. Invivo knockdown of VEGFA 
and PKD2 in mice results in inhibition of angiogenesis and tumor growth (Azoitei et al., 2010). 
Strikingly, VEGFA is very highly abundant in our analysis on gastric adenocarcinoma samples. 
DKK3 
Dickkopf related-protein 3 (DKK3) is found less abundant in the gastric adenocarcinomas. Often 
referred as one of the vital tumor suppressor genes, DKK3 is often missing in various cancer 
cells. Wnt signaling which is widely studied in biology of cancers can be modulated by varying 
concentrations of other soluble including DKK3. DKK3 at protein level is very less in abundance 
in gastric and colon cancer cells (Byun et al., 2005). More detailed molecular analysis of gastric 
cancers illustrated epigenetic down-regulation leading to the inactivation in the translation of 
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DKK3 genes in gastric cancers (Sato et al., 2007). More recently, plasmid-mediated functional 
resurrection of DKK3 in gastric cancer cells decreased the aggressiveness and migration of the 
cells indicating the possible tumor suppressor role of DKK3 in gastric cancer. Moreover, DKK3 
expression in gastric cancers negatively correlated with the tumor size, metastasis and grade of 
the tumor indicating the prognostic significance of it in gastric cancer (Xu et al., 2012).  
From the above exhibited significantly abundant proteins in gastric adenocarcinomas, we suggest 
that similar mechanisms of oncogenesis may be the causes of cancer in sets of samples in 
analyses. The stability and consistency of some of the markers can be a boon to available 
molecular diagnostics as all of them are studied at the protein level. A signature of top sixteen 
proteins from table 3 will help not only to predict prognosis but also to establish individual-based 
treatment strategy as the comparisons here are made matching the healthy controls and the 
gastric adenocarcinoma tissues after surgical resection from the same patient.  
 
 
Conclusions 
 
 
73 
 
5 Conclusions 
The current study presented here focused on the application of complex antibody microarrays as 
a diagnostic and prognostic tool in human cancers. In the first part of the study, protein profiles 
of non-muscle invasive bladder cancer samples were studied and a signature of 20 proteins was 
identified to predict the recurrence of the cancer. Apart from the prediction of recurrence with 
high specificity and sensitivity, the important molecular mechanisms that may lead to recurrence 
of cancer were also identified. The results from this analysis will prove to be efficient in 
predicting the recurrence of cancer by the application of the protein signature in large sets of 
non-muscle bladder cancer samples with appropriate follow-up time. Moreover, this effective 
prediction will aid the clinicians to develop an optimal strategy to follow-up and treat the 
patients. 
In the second part of the study, analysis of gastric adenocarcinoma samples by two different 
methods of incubations on the antibody microarrays identified a set of 16 proteins highly 
differentially regulated between healthy controls and cancer tissues. Proteins identified included 
many validated and well studied therapeutic targets which are under clinical trials. A strong 
literature search on the identified proteins provided more insights on the molecular mechanisms 
of oncogenesis and metastasis in gastric tissues. The results from this analysis will help 
clinicians to identify patients with higher risk of metastasis and death occurrence. Validation of 
the protein profile in large sets of tumors will favor individual-based treatment regimen for 
gastric cancer. More functional validations on the identified targets will help in the development 
of therapeutics to treat gastric adenocarcinoma. 
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7. Appendix 
7.1 Supplementary table S1 
Supplementary table S1. List of the sixteen proteins with the significant expression variations 
between healthy controls and tumours. Log fold changes in expression and the related adjusted 
p-values are shown.  
 
Sl.No. Uniprot 
Entryname 
Uniprot 
accession 
adjusted 
P Value 
log 
Fold 
change 
1 THYG_HUMAN P01266 8.65E-30 -1.86 
2 IL2_HUMAN P60568 1.90E-22 -1.58 
3 PTEN_HUMAN P60484 1.20E-15 -1.54 
4 IL4_HUMAN P05112 7.06E-13 -2.14 
5 IFNG_HUMAN P01579 6.67E-12 -1.16 
6 VEGFA_HUMAN P15692 1.68E-09 -0.93 
7 FUS_HUMAN P35637 3.25E-09 -0.66 
8 LAP2A_HUMAN P42166 0.002 0.30 
9 TR10A_HUMAN O00220 0.004 0.53 
10 TNR21_HUMAN O75509 0.008 -0.52 
11 ALBU_HUMAN P02768 0.010 0.89 
12 ICAM1_HUMAN P05362 0.012 0.26 
13 TR10A_HUMAN O00220 0.015 0.36 
14 CDN1C_HUMAN P49918 0.045 0.30 
15 IL6_HUMAN P05231 0.046 -0.20 
16 ETS1_HUMAN P14921 0.046 -0.39 
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7.2 Supplementary table S2 
Supplementary table S2. List of the two hundred and fifty five proteins with the significant 
expression variations between recurrent and non-recurrent non-muscle invasive bladder cancer. 
Log fold changes in expression and the related adjusted p-values are shown.  
Sl.No. Uniprot 
Entryname 
Uniprot 
accession 
adjusted 
P Value 
log Fold 
change 
1 LMNA_HUMAN P02545 3.32E-09 0.72 
2 YBOX1_HUMAN P67809 1.87E-08 0.52 
3 JUN_HUMAN P05412 1.27E-07 0.50 
4 TIA1_HUMAN P31483 2.13E-07 -0.39 
5 SMAD3_HUMAN P84022 2.13E-07 -0.59 
6 PABP1_HUMAN P11940 2.13E-07 -0.36 
7 AKT3_HUMAN Q9Y243 2.47E-07 0.48 
8 CDN1A_HUMAN P38936 3.38E-07 -0.52 
9 LYAM1_HUMAN P14151 9.62E-07 -0.52 
10 YETS2_HUMAN Q9ULM3 5.28E-06 0.32 
11 AKTIP_HUMAN Q9H8T0 5.38E-06 -0.35 
12 PRI1_HUMAN P49642 1.04E-05 -0.36 
13 HSP7C_HUMAN P11142 1.04E-05 -0.34 
14 RSSA_HUMAN P08865 1.07E-05 -0.35 
15 GRM1A_HUMAN Q96CP6 1.10E-05 0.27 
16 TPA_HUMAN P00750 1.14E-05 0.23 
17 ZBT17_HUMAN Q13105 1.14E-05 -0.55 
18 CADH1_HUMAN P12830 1.15E-05 0.33 
19 LAMP2_HUMAN P13473 1.15E-05 0.26 
20 JUN_HUMAN P05412 1.34E-05 0.48 
21 LIFR_HUMAN P42702 2.17E-05 0.30 
22 TOP2A_HUMAN P11388 2.17E-05 0.48 
23 SPS2L_HUMAN Q9NUQ6 2.20E-05 -0.23 
24 UBIQ_HUMAN P62988 2.47E-05 0.24 
25 NFAC4_HUMAN Q14934 2.47E-05 0.35 
26 SF3B3_HUMAN Q15393 2.47E-05 0.32 
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27 2DMB_HUMAN P28068 3.41E-05 -0.35 
28 FAK1_HUMAN Q05397 3.93E-05 -0.36 
29 IFNG_HUMAN P01579 3.95E-05 -0.46 
30 SP1_HUMAN P08047 4.14E-05 -0.36 
31 ACTN1_HUMAN P12814 4.31E-05 -0.36 
32 TIE1_HUMAN P35590 6.17E-05 -0.30 
33 TIMP1_HUMAN P01033 6.32E-05 -0.33 
34 MMP13_HUMAN P45452 6.32E-05 0.25 
35 VTNC_HUMAN P04004 6.76E-05 -0.51 
36 K1C17_HUMAN Q04695 0.0002 -0.20 
37 NFKB1_HUMAN P19838 0.0002 0.32 
38 KLF5_HUMAN Q13887 0.0002 0.37 
39 NAP1_HUMAN Q9BU70 0.0002 -0.27 
40 RL10_HUMAN P27635 0.0002 -0.28 
41 MMP1_HUMAN P03956 0.0002 -0.26 
42 CDKN3_HUMAN Q16667 0.0002 -0.33 
43 CD59_HUMAN P13987 0.0003 -0.33 
44 PO2F2_HUMAN P09086 0.0003 -0.35 
45 MPIP2_HUMAN P30305 0.0003 -0.28 
46 FRAP_HUMAN P42345 0.0003 -0.27 
47 IRS2_HUMAN Q9Y4H2 0.0003 -0.33 
48 B2LA1_HUMAN Q16548 0.0003 0.24 
49 ERBB2_HUMAN P04626 0.0004 -0.24 
50 CASP3_HUMAN P42574 0.0004 0.40 
51 FINC_HUMAN P02751 0.0004 -0.31 
52 LAC_HUMAN P01842 0.0004 -0.26 
53 AURKB_HUMAN Q96GD4 0.0004 -0.33 
54 MPP3_HUMAN Q13368 0.0004 -0.21 
55 CD2A2_HUMAN Q8N726 0.0004 -0.32 
56 SOX9_HUMAN P48436 0.0004 0.23 
57 EPCAM_HUMAN P16422 0.0004 -0.30 
58 TSP3_HUMAN P49746 0.0004 -0.24 
59 O00446_HUMAN O00446 0.0005 0.25 
60 CP3A7_HUMAN P24462 0.0006 -0.23 
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61 THYG_HUMAN P01266 0.0006 -0.34 
62 NMDE3_HUMAN Q14957 0.0006 -0.27 
63 IL15_HUMAN P40933 0.0006 -0.80 
64 AQP1_HUMAN P29972 0.0006 0.24 
65 LAT1_HUMAN Q01650 0.0006 -0.24 
66 GSHB_HUMAN P48637 0.0006 0.17 
67 RPB3_HUMAN P19387 0.0007 -0.23 
68 K1C19_HUMAN P08727 0.0007 0.21 
69 PAK2_HUMAN Q13177 0.0007 0.20 
70 ZN593_HUMAN O00488 0.0008 0.24 
71 MYD88_HUMAN Q99836 0.0008 0.22 
72 IL8_HUMAN P10145 0.0009 -0.23 
73 SEP15_HUMAN O60613 0.0010 -0.21 
74 CUL2_HUMAN Q13617 0.0010 -0.24 
75 TNF13_HUMAN O75888 0.0010 -0.24 
76 EPHB3_HUMAN P54753 0.001 0.21 
77 APBA1_HUMAN Q02410 0.001 0.25 
78 MK10_HUMAN P53779 0.001 -0.18 
79 IL10_HUMAN P22301 0.001 0.22 
80 GDN_HUMAN P07093 0.001 -0.26 
81 HMMR_HUMAN O75330 0.001 -0.26 
82 OLFM4_HUMAN Q6UX06 0.001 -0.23 
83 LYAM1_HUMAN P14151 0.001 0.21 
84 CISY_HUMAN O75390 0.001 -0.30 
85 ID2_HUMAN Q02363 0.001 -0.28 
86 MUTED_HUMAN Q8TDH9 0.001 -0.29 
87 SEPR_HUMAN Q12884 0.001 -0.25 
88 TR10A_HUMAN O00220 0.002 -0.37 
89 K2C8_HUMAN P05787 0.002 -0.19 
90 TNFB_HUMAN P01374 0.002 0.20 
91 ANFB_HUMAN P16860 0.002 0.19 
92 CP1B1_HUMAN Q16678 0.002 -0.30 
93 BRPF3_HUMAN Q9ULD4 0.002 -0.18 
94 GBRB1_HUMAN P18505 0.002 -0.21 
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95 AP4B1_HUMAN Q9Y6B7 0.002 -0.21 
96 SIA7F_HUMAN Q969X2 0.002 0.18 
97 HXC11_HUMAN O43248 0.002 -0.17 
98 PIGC_HUMAN Q92535 0.002 -0.15 
99 TRI22_HUMAN Q8IYM9 0.002 -0.23 
100 OSTP_HUMAN P10451 0.002 -0.23 
101 ZO2_HUMAN Q9UDY2 0.002 0.19 
102 PO2F1_HUMAN P14859 0.003 -0.23 
103 ARI4A_HUMAN P29374 0.003 0.16 
104 KPYM_HUMAN P14618 0.003 -0.20 
105 SHIP1_HUMAN Q92835 0.003 -0.24 
106 K1C18_HUMAN P05783 0.003 -0.15 
107 LYAM1_HUMAN P14151 0.003 0.20 
108 ENOG_HUMAN P09104 0.004 0.19 
109 IFNG_HUMAN P01579 0.004 -0.24 
110 RL29_HUMAN P47914 0.004 0.24 
111 EWS_HUMAN Q01844 0.004 0.41 
112 HSF1_HUMAN Q00613 0.004 -0.14 
113 KLF8_HUMAN O95600 0.004 0.29 
114 TR10B_HUMAN O14763 0.004 -0.20 
115 NFKB2_HUMAN Q00653 0.004 -0.22 
116 NEP_HUMAN P08473 0.004 -0.19 
117 IFM1_HUMAN P13164 0.005 0.14 
118 RPN2_HUMAN P04844 0.005 0.18 
119 TGFA_HUMAN P01135 0.005 0.18 
120 CP3A5_HUMAN P20815 0.005 0.13 
121 CATA_HUMAN P04040 0.006 -0.47 
122 MLH1_HUMAN P40692 0.006 -0.17 
123 MAGA8_HUMAN P43361 0.006 -0.16 
124 P53_HUMAN P04637 0.006 -0.19 
125 IFNA1_HUMAN P01562 0.006 -0.33 
126 KSYK_HUMAN P43405 0.006 0.18 
127 K1C14_HUMAN P02533 0.007 0.17 
128 CCL4_HUMAN P13236 0.007 -0.23 
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129 TR13C_HUMAN Q96RJ3 0.007 0.26 
130 STK19_HUMAN P49842 0.007 0.15 
131 FLOT1_HUMAN O75955 0.007 0.18 
132 FANCC_HUMAN Q00597 0.007 -0.17 
133 Q16590_HUMAN Q16590 0.007 -0.22 
134 EF1G_HUMAN P26641 0.007 0.14 
135 PIR_HUMAN O00625 0.008 -0.28 
136 EDN1_HUMAN P05305 0.008 -0.18 
137 PCNA_HUMAN P12004 0.008 -0.17 
138 S100P_HUMAN P25815 0.008 -0.15 
139 CDC5L_HUMAN Q99459 0.008 -0.19 
140 MUC6_HUMAN Q6W4X9 0.009 -0.31 
141 KLH12_HUMAN Q53G59 0.009 -0.17 
142 DNLI3_HUMAN P49916 0.009 0.16 
143 MAD1_HUMAN Q05195 0.009 0.18 
144 CTRB1_HUMAN P17538 0.009 -0.14 
145 SRGEF_HUMAN Q9UGK8 0.009 -0.15 
146 OSTP_HUMAN P10451 0.009 -0.15 
147 TIMP2_HUMAN P16035 0.010 -0.22 
148 GRPR_HUMAN P30550 0.010 -0.28 
149 VIME_HUMAN P08670 0.010 -0.21 
150 TOP2A_HUMAN P11388 0.010 -0.23 
151 MUC2_HUMAN Q02817 0.010 0.15 
152 MLH3_HUMAN Q9UHC1 0.010 0.18 
153 MOT4_HUMAN O15427 0.010 -0.19 
154 VEGFA_HUMAN P15692 0.010 -0.29 
155 ID1_HUMAN P41134 0.010 -0.23 
156 EI2BA_HUMAN Q14232 0.011 -0.17 
157 HNRPC_HUMAN P07910 0.011 -0.15 
158 CASP9_HUMAN P55211 0.014 0.30 
159 ST14_HUMAN Q9Y5Y6 0.011 0.18 
160 VAS1_HUMAN Q15904 0.011 -0.19 
161 SMAD4_HUMAN Q13485 0.013 -0.13 
162 MTA1_HUMAN Q13330 0.013 0.14 
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163 CAV3_HUMAN P56539 0.013 0.15 
164 PTEN_HUMAN P60484 0.014 -0.26 
165 LUM_HUMAN P51884 0.014 -0.15 
166 TMED2_HUMAN Q15363 0.014 0.23 
167 CD81_HUMAN P60033 0.014 0.21 
168 MD2L1_HUMAN Q13257 0.014 0.14 
169 DC12_HUMAN Q96FZ2 0.015 0.17 
170 ICAM1_HUMAN P05362 0.015 -0.16 
171 TMM54_HUMAN Q969K7 0.015 -0.14 
172 IL1RA_HUMAN P18510 0.015 0.16 
173 TNFA_HUMAN P01375 0.015 -0.24 
174 RBM42_HUMAN Q9BTD8 0.015 -0.13 
175 TNF13_HUMAN O75888 0.015 0.18 
176 RARB_HUMAN P10826 0.015 -0.14 
177 IL6RA_HUMAN P08887 0.015 0.13 
178 TR10A_HUMAN O00220 0.016 -0.22 
179 PHB_HUMAN P35232 0.017 -0.13 
180 CAH2_HUMAN P00918 0.017 0.15 
181 NPT1_HUMAN Q14916 0.018 -0.19 
182 IGF2_HUMAN P01344 0.018 -0.19 
183 MMP1_HUMAN P03956 0.018 -0.19 
184 PSB4_HUMAN P28070 0.018 -0.14 
185 MK03_HUMAN P27361 0.018 0.20 
186 SODC_HUMAN P00441 0.018 -0.16 
187 MCP_HUMAN P15529 0.019 0.13 
188 MTHR_HUMAN P42898 0.020 -0.12 
189 BEX3_HUMAN Q00994 0.021 0.13 
190 GPX4_HUMAN P36969 0.021 0.18 
191 MTA2_HUMAN O94776 0.021 -0.13 
192 IL2_HUMAN P60568 0.021 -0.23 
193 FGF7_HUMAN P21781 0.021 -0.14 
194 ICAM1_HUMAN P05362 0.022 -0.14 
195 1C01_HUMAN P30499 0.023 0.15 
196 HSBP1_HUMAN O75506 0.024 0.17 
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197 TRFE_HUMAN P02787 0.024 -0.41 
198 P5CR1_HUMAN P32322 0.025 0.16 
199 PGH2_HUMAN P35354 0.025 0.17 
200 CATD_HUMAN P07339 0.027 0.30 
201 CCR7_HUMAN P32248 0.025 0.17 
202 SORL_HUMAN Q92673 0.028 0.15 
203 AIFM1_HUMAN O95831 0.030 0.26 
204 CBX3_HUMAN Q13185 0.029 -0.13 
205 L1CAM_HUMAN P32004 0.031 -0.20 
206 BAX_HUMAN Q07812 0.031 0.16 
207 IBP3_HUMAN P17936 0.031 0.14 
208 MK04_HUMAN P31152 0.031 0.11 
209 CFLAR_HUMAN O15519 0.031 0.15 
210 SYSC_HUMAN P49591 0.031 -0.17 
211 IL4_HUMAN P05112 0.031 -0.14 
212 ETS2_HUMAN P15036 0.031 -0.18 
213 ZG16_HUMAN O60844 0.032 0.11 
214 MMP10_HUMAN P09238 0.032 0.13 
215 T4S4_HUMAN P48230 0.032 0.13 
216 P63_HUMAN Q9H3D4 0.032 0.11 
217 BRAF1_HUMAN P15056 0.032 -0.22 
218 RL27A_HUMAN P46776 0.032 -0.15 
219 WNT2B_HUMAN Q93097 0.033 0.13 
220 CAD13_HUMAN P55290 0.033 -0.14 
221 IL1R2_HUMAN P27930 0.033 0.13 
222 HXA9_HUMAN P31269 0.033 -0.11 
223 O14997_HUMAN O14997 0.034 0.15 
224 HERP1_HUMAN Q15011 0.034 -0.20 
225 TIP_HUMAN Q8TB96 0.034 -0.16 
226 NEK2_HUMAN P51955 0.034 0.12 
227 DHRS2_HUMAN Q13268 0.036 -0.15 
228 HMGB1_HUMAN P09429 0.035 0.14 
229 CENPF_HUMAN P49454 0.035 -0.11 
230 PO5F1_HUMAN Q01860 0.036 0.20 
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231 ECHM_HUMAN P30084 0.036 -0.57 
232 TR10B_HUMAN O14763 0.037 0.22 
233 S19A1_HUMAN P41440 0.036 -0.12 
234 FGF2_HUMAN P09038 0.037 -0.22 
235 ABCG2_HUMAN Q9UNQ0 0.037 -0.12 
236 RAB1A_HUMAN P62820 0.037 0.12 
237 TBB5_HUMAN P07437 0.037 0.15 
238 LEUK_HUMAN P16150 0.039 0.18 
239 CKAP2_HUMAN Q8WWK9 0.039 0.13 
240 NUPR1_HUMAN O60356 0.039 -0.13 
241 TNR6_HUMAN P25445 0.041 -0.29 
242 VINEX_HUMAN O60504 0.040 -0.12 
243 PIGT_HUMAN Q969N2 0.040 0.13 
244 CAV2_HUMAN P51636 0.041 0.18 
245 UN93B_HUMAN Q9H1C4 0.042 -0.16 
246 FASTK_HUMAN Q14296 0.042 0.13 
247 VGFR2_HUMAN P35968 0.042 -0.14 
248 SYG_HUMAN P41250 0.042 0.14 
249 TGFB2_HUMAN P61812 0.042 -0.12 
250 IL13_HUMAN P35225 0.043 0.18 
251 S1PR1_HUMAN P21453 0.043 0.12 
252 CCNB1_HUMAN P14635 0.043 -0.15 
253 CD44_HUMAN P16070 0.043 -0.16 
254 ENC1_HUMAN O14682 0.047 -0.16 
255 PLSL_HUMAN P13796 0.047 -0.11 
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7.3 Supplementary figure S1 
Supplementary figure S1. Differential abundance of apoptotic-related proteins between 
recurrent and non-recurrent non-muscle invasive bladder cancer. Highly abundant proteins were 
coloured red and less abundant proteins were coloured green. KEGG pathway analysis software 
was used to identify the proteins. 
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7.4 Supplementary figure S2 
Supplementary figure S2. Differential abundance of proteins between recurrent and non-
recurrent non-muscle invasive bladder cancer in various cancer pathways. Highly abundant 
proteins were coloured red and less abundant proteins were coloured green. KEGG pathway 
analysis software was used to identify the proteins. 
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